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1. PRECISION MEDICINE  
Personalized or precision medicine is an emerging approach to the treatment and 
prevention of disease, which takes into account the individual variability of genes, 
environment and lifestyles of each person1. The study of a biological system is one of the 
major challenges of system biology and seeks to reveal the organization and interactions 
between the different cellular mechanisms that underlie complex processes. Personalized 
medicine includes preventive, diagnostic and therapeutic measures optimally tailored to an 
individual and aimed at applying more effective therapies and reducing side effects. The 
diffusion and improvement of molecular characterization technologies we have witnessed in 
recent years allow us to simultaneously study the different levels of biological information. 
These levels involve the study of DNA (genomics), proteins (proteomics) as well as the 
analysis of chemical fingerprints left by physiological processes (metabolomics); these areas 
of study are defined as "omics". Proteins and metabolites are highly dependent on lifestyle, 
environment, drugs and the physiological state of each individual so they are necessary to 
fully describe the phenotype of a disease.  
The proteomic and metabolomic approaches allow the global identification, not guided by a 
priori hypothesis, of thousands of proteins and hundreds of metabolites present in a 
biological fluid and the evaluation of how these can vary in the presence of a specific disease 
compared to a non-pathological condition, allowing to characterize and discriminate 
between different study groups2. 
The different functional levels analyzed by omics sciences are integrated with each other in 
the context of system biology, a new field of science, which offers an innovative approach to 
the study of biological systems. The reductionist approach that has been used in medicine to 
date studies cellular components separately and opposes the holistic approach that 
considers a biological system as a complex network of dynamic interactions between its 
components, such as genes, mRNA, proteins and metabolites that identify the so-called 
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The understanding of networks of interactions through system biology can lead to a more 
complete view of the processes involved in the disease. The identification of thousands of 
proteins and hundreds of metabolites can help in the new disease biomarkers discovery and 
therefore in development of new methodologies for the diagnosis or treatment of a 
pathological state.  
Both omics and more traditional research identify biomarkers for diagnostic, prognostic, 
screening and monitoring purposed.  
Translational medicine has the task of rapidly and effectively translating scientific discoveries 
into clinical practice, through biomarkers qualification, verification and validation and 
through a two-way relationship with scientists, producers, clinicians and epidemiologists3. 
 
 








Chiara Lavarello, Ph.D. Thesis in Chemical Sciences and Technologies. 
 
 
High Resolution Mass Spectrometry (HRMS) coupled with Ultra High Performance Liquid 
Chromatography (UHPLC) plays a fundamental role in characterizing and quantifying disease 
markers as well as in describing the molecular mechanisms of the biological processes in 
which they are involved4.  
This latest generation technology has become in recent years the investigative tool of 
excellence, thanks to which it is possible to "untargeted" the study of thousands of analytes 
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2. THE PROJECT 
My PhD project is the result of a collaboration between the Department of Chemistry and 
Industrial Chemistry of the University of Genoa and Proteomics and Clinical Metabolomics 
Laboratory of the Institute for Scientific Research (IRCCS) Giannina Gaslini.  
The collaboration is consistent with the new birth of “Federazione Nazionale degli Ordini dei 
Chimici e Fisici”; thanks to 3/18 law the profession of chemist in Italy has been recognized as 
being of fundamental importance for the health and safety of the community. 
My PhD project is divided into two parts that have in common the development of 
innovative analytical methods in High Resolution Mass Spectrometry with Orbitrap 
technology, for the study of proteome and metabolome in complex biological matrices. 
During the first two years, the proteome of auto inflammatory diseases was studied, while in 
the last year a spectral MSMS library and Accurate Mass Retention Time (AMRT) Database of 
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3. INSTRUMENTATIONS  
In both projects High Resolution Mass Spectrometer coupled to UHPLC were used to 
separate and to identify and quantify proteins and metabolites in biological matrix such as 
cells, cerebrospinal fluids, urine and plasma.  
RS Ultimate 3000 HPLC coupled with Orbitrap Fusion Tribrid was used to study the proteome 
of inflammatory diseases, while Vanquish Horizon UHPLC coupled with the Q-Exactive 
Hybrid Quadrupole-Orbitrap mass spectrometer was used to build an accurate database of 
masses and retention times. The choice was dictated by the fact that nano and micro fluxes 
for proteomics and metabolomics respectively are required. 
Liquid chromatography allows the separation of the analytes (whether polar, thermolabile or 
hardly volatile) contained in the sample on the basis of their distribution between the mobile 
and stationary phases. The stationary phase is formed by packed solid particles of very fine 
grain size (between 1.8 and 10 µm), housed inside a column suitable to withstand the high 
pressures with which the instrument works.  
The mobile phase may consist of a pure liquid or a solvent mixture of known composition, 
which flows through the stationary phase of the chromatographic column. The elution can 
be isocratic, in which the solvents flow with the same composition throughout the 
chromatographic run, or polarity gradient, in which the relative quantities of solvents vary 
during the course of the analysis. The affinity with the stationary phases is given by the 
different polarity and the different chemical characteristics of the compounds of the mixture 
to be separated: analytes which have little affinity with the stationary phase are not retained 
and therefore elute quickly transported by the mobile phase; on the other hand, analytes 
which have greater affinity will be retained and will come out in a longer time. 
Mass spectrometry is an analytical technique that allows the identification and 
quantification of analytes present in complex mixtures based on the different mass-to-
charge ratio (m/z) of ions generated by ionization. The main strengths of these mass 
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where m is the peak mass and Δm is the peak amplitude at half its height (FWHM: Full With 
at Half Maximum peak height).  
Mass Accuracy is a parameter that directly depends on the instrument's ability to separate 
adjacent peaks and therefore resolution. The estimate of mass accuracy is expressed by the 
value of the error on the measured mass, expressed in parts per million (ppm), is 
determined by the function8,9:  
  






where mt= exact theoretical mass and ms= accurate mass measured instrumentally. The 
ability to measure the mass of a compound with adequate accuracy directly determines the 
possibility of obtaining its elementary composition10. The instrument must be carefully 
calibrated: external calibration is performed by direct infusion of a mixture of known 
compounds (caffeine, MRFA tetrapeptide and Ultramark 1621), in a mass range of 150 to 
2000 m/z and allows a mass accuracy of 3 ppm. Improved accuracy of less than 1 ppm can 
be achieved using an internal calibration.  
Orbitrap‐based instruments have established themselves firmly in the field of proteomics, 
biopharmaceuticals, metabolomics and metabolite analysis and made a high resolution mass 
spectrometer accessible to most life science laboratories. Moreover, it has gained increased 
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3.1  Ultimate 3000 and Vanquish Orizon UHPLC 
The two UHPLC are both suitable for processing large quantities of samples thanks to the 
robustness of the hydraulic system. They differ in the flow they work with. RS-UHPLC 
Ultimate 3000 is characterized by a wide flow/pressure range allowing the application of 
UHPLC on nano scale and at the same time allowing to have maximum resolution and 
analytical speed, even for tryptic digests of maximum complexity. The Vanquish UHPLC for 
the metabolomics project uses micro fluxes. 
The fundamental components are: 
 degaser, a system that allows to eliminate any bubbles present in the solvent that 
could compromise the chromatographic efficiency and possibly the operation of the 
detectors;  
 housing of the analytical and nano pump;  
 autosampler; 
 the thermostatic compartment in which the analytical column is housed. The column 
is certainly a fundamental part of the instrument: the columns on the market are 
many and differ in the type of stationary phase, length, diameter and the different 
dimensions of the pores of the stationary phase.  
In reverse-phase (RP) chromatography, the stationary phase has a hydrophobic 
character, while the mobile phase has a polar character. The interactions in RP-HPLC 
are considered to be the hydrophobic forces and these forces are caused by the 
energies resulting from the disturbance of the dipolar structure of the solvent. The 
separation is typically based on the partition of the analyte between the stationary 
phase and the mobile phase. The solute molecules are in equilibrium between the 
hydrophobic stationary phase and partially polar mobile phase. The more 
hydrophobic molecule has a longer retention time while the ionized organic 
compounds, inorganic ions and polar metal molecules show little or no retention 
time.  
HILIC or Hydrophilic Interaction Liquid Chromatography is a technique for separation 
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organic mobile phase over a polar stationary phase. This forms a water enriched 
layer next to the stationary phase. The hydrophilic analytes partition into this layer 
and as the mobile phase becomes more hydrophilic, they are eluted in order of 
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3.2  Orbitrap Fusion Tribrid e Orbitrap Q-Exactive 




Figure 2: Orbitrap Fusion Tribrid scheme. 
 
 Electrospray Interface 
ESI (Electrospray Ionization) interface, as well as the Atmospheric Pressure Chemical 
Ionization (APCI) interface are required to couple liquid chromatography with mass 
spectrometers and it converts the analytes in solution into gas-phase ions. ESI is a "soft" 
ionization source: it causes a low sample fragmentation so that the mass spectrum presents 
protonated [M + H]+ , deprotonated [M- H]- or adduced ions of the analyte with ionic 
species such as Na+ , K+ etc. ESI is particularly suitable for the ionization of polar compounds 
and not only small molecules, but also proteins, peptides, industrial polymers thanks to the 
formation of multicharged ions. Electrospray ionization takes place at atmospheric pressure 
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The analytes previously separated by chromatography, are injected through a metal capillary 
into the ionization chamber of the source, the input is facilitated by the application of a high 
electrical potential that can be negative or positive depending on the analytes. Coaxial to the 
capillary there is a gas flow (sheath gas) with the function of nebulizing the solution in a thin 
aerosol at the exit of the capillary. A spray of charged droplets, with a diameter of a few 
microns (1-60 µm), is thus formed and directed towards the opening on the counter-
electrode made up of a capillary and a skimmer. The desolvation is favored by the 
temperature of the source and the flow of an auxiliary gas which, applied externally has the 
task of assisting the sheath gas in the nebulization of the sample and the evaporation of the 
solvent. The process continues until the "Rayleigh limit" is reached, a limit in which the 
surface tension of the drop can no longer withstand the Coulumbian repulsion between the 
charges with a consequent "Coulumbian" explosion: the drops disintegrate obtaining smaller 
dimensions. The mechanism is repeated until all the solvent has evaporated with 
consequent formation of analyte desolved ions in the gas phase, which can have unit or 
multiple charges. The ion swipe cone forms a mechanical barrier that protects the transfer 
capillary from larger droplets and particulate matter. Ions then pass through the ion transfer 
capillary into the mass detector. 
  S – Lens 
At the exit of the capillary is the S-Lens which focuses the ions towards the opening of the 
skimmer. S-lens is a parameter that must be carefully adjusted, since it is of great 
importance in the intensity with which an ion species will be revealed, representing a 
discriminat between the degree of declusterization and fragmentation of an ion.  
 Active beam guide. 
Prevents neutral molecules from entering the quadrupole, improving the robustness of the 
system. 
 Quandrupolo Q. 
The quadrupole has a "filter" function and selects ions with an isolation width of less than 
0.4 amu to achieve excellent sensitivity and selectivity. In particular, such instruments can 
select ions virtually instantaneously due to the fast switching times of the quadrupole and it 
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ability to fill the HCD cell or the C‐trap with ions while a previous Orbitrap detection cycle is 
still ongoing, the system achieved a very high duty cycle. By allocating most of the analysis 
time (up to 70–95%) just for accumulating ions, the sensitivity is maximized and the negative 
impact that low ion currents could have on acquisition speed and quality of spectra is 
prevented. 
 C – trap. 
 The C-trap is essentially a "flatpole" ion guide that has both a curved central axis and a slot 
in the electrode closest to the Orbitrap.  The trap is typically operated with ~1 mTorr of 
nitrogen, allowing very effective collisional cooling of ions in its RF field.  Once the ions have 
accumulated/cooled sufficiently within the C-trap, the RF amplitude is quickly ramped down 
(in ~100-200 ns).  The absence of an RF field means that the ions will no longer be confined 
radially within the trap's volume.  Once the RF amplitude has dropped, the ions must be 
quickly pulled out of the trap so that they don't strike the trap electrodes.  This is 
accomplished by appropriate DC potentials.  For positive ions, the electrode furthest from 
the Orbitrap is the most positive, and the slotted electrode closest to the Orbitrap is the 
least positive.  As a result, positive ions are pushed toward the Orbitrap, exiting the C-trap 
through its slotted electrode.  They are subsequently accelerated/focused into the 
Orbitrap.  Since the ions had very low kinetic energy within the C-trap, they have a narrow 
distribution of kinetic energies upon entering the Orbitrap.  Additionally, the rapid changes 
in RF and DC potentials that are used to empty the C-trap mean that the ions enter the 
Orbitrap in a narrow time window. 
 Ion Routing Multipole (Higher Energy Collisional Dissociation, HCD). 
The HCD collision cell consists of a multipole mounted inside a connected metal tube, direct 
line with the C-Trap and filled with nitrogen. Through collisions with the gas molecules, the 
precursor ions are fragmented, producing high-energy fragmentation spectra that provide 
information complementary to that obtained from the ion trap. The fragments obtained are 













The Orbitrap12 is a mass analyzer, consisting of an internal spindle-shaped electrode, placed 
coaxially to an external bell-shaped electrode. Ions are injected into the volume between the 
central and outer electrodes essentially along a tangent through a specially machined slot 
with a compensation electrode (a “deflector”) in one of the outer electrodes. With voltage 
applied between the central and outer electrodes, a radial electric field bends the ion 
trajectory toward the central electrode while tangential velocity creates an opposing 
centrifugal force. With a correct choice of parameters, the ions remain on a nearly circular 
spiral inside the trap. At the same time, the axial electric field caused by the special conical 
shape of electrodes pushes ions toward the widest part of the trap initiating harmonic axial 
oscillations. Outer electrodes are then used as receiver plates for image current detection of 
these axial oscillations. The digitized image current in the time domain is Fourier-
transformed into the frequency domain in the same way as in FTICR and then converted into 
a mass spectrum. 
 




 Dual linear ion trap 
The linear ion trap is a low-resolution mass analyzer that can store, isolate and fragment ions 
and detect them using its detectors. To produce a mass spectrum, direct current (dc) and 
radio frequency (rf) voltages are varied in the ion trap to sequentially eject ions according to 
their m/z ratio. By varying only the RF voltage, the analyser can first expel all the ions, except 
some precursor ions and then exploiting the collisions with the helium molecules it contains, 
fragmenting them to obtain the ions produced. The ions produced are then ejected from the 
trap according to their m/z ratio, thus obtaining an MSMS spectrum.  
Dual linear ion trap was chosen as a ‘partner’ for the Orbitrap mass analyzer due to its very 
high sensitivity, superb control of the ion population, short cycle time, and MSn capability.  
Depending on the requirements for the analysis, the two analyzers could be used 
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automatic gain control (AGC), wherein a short pre‐scan in the linear trap is used to 
determine the ion current within the mass range of interest, hence enabling storage of a 
defined number of ions (‘AGC target value’) in the subsequent analytical scan. The AGC 
feature, in combination with the precise determination of the ion injection time, allows the 
instrument to be used for accurate quantitative analyses and ensures the stability and 
accuracy of m/z measurements by the Orbitrap analyzer, as control of the ion packet 
decreases the rate of space charging. It is worth pointing out that the MS/MS spectra 
generated in the linear ion trap and detected either in the linear trap or the Orbitrap 
analyzer are very similar, with the only major difference being the resolution and mass 
accuracy of the observed peaks. Meanwhile, the linear trap requires about an order of 
magnitude fewer ions for an analytically useful spectrum due to its very high transmission 
and single‐ion detection capability11. 
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Figure 3 shows the scheme of the fundamental constituents of the Orbitrap Q-exactive 
instrument; as can be easily seen by comparing Figure 2 with Figure 3, the Q-Exactive 
spectrometer lacks the linear trap. This different configuration allows only certain types of 
acquisitions, those that would involve the use of the linear trap for low-energy 
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3.3  Acquisition mode 
In LC-MS/MS methods, three events occur in the mass spectrometer:  
1. ionization: analytes elute into the mass spectrometer from the HPLC and are ionized;  
2. MS1 scan: the abundance and mass-to-charge ratios (m/z) of all ions eluting at a given 
time are measured. This acquisition mode can be conducted in both the low resolution 
ion trap and the high resolution orbital trap, but usually is conducted in Orbitrap. The 
chromatogram is given by the Total Ion Current (TIC) as a function of the retention time; 
3. MS2 scan: some or all detected ions are fragmented, the abundances and m/z’s of the 
fragments in orbital trap or ion trap are measured and recorded.  
Different LC-MS/MS methods vary in how ions are selected and measured in the MS2 scan. 
Figure 4 shows a scheme of how analytes are isolated, fragmented and analyzed by a mass 
spectrometer working on DDA, MRM, PRM, or DIA modes13. 
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In DDA, MRM and PRM, single precursor ions are isolated, fragmented and analyzed in an 
MS2 scan by the mass spectrometer. In DDA mode, the precursor ions are chosen by the 
instrument on the basis of abundance. In MRM and PRM, the precursor ions to be analyzed 
are fixed by the user.  
DIA is different form the methods above in that all precursor ions within a selected mass 
range are isolated, fragmented and analyzed in a single MS2 scan. In MS1 scan the analytes 
ions entering the mass spectrometer at a given time are identified; in MS2 scan the 
fragments of all (or some) of precursors that are in the mass spectrometer at a given time 
are identified. 
 Data Dependent Analysis (DDA). 
In DDA, a subset of the most abundant ions reaching the mass spectrometer detector during 
an MS1 scan are individually isolated and fragmented in sequential MS2 scans and each MS2 
scan can be analyzed with a database search algorithm14,15. Currently, most instruments can 
perform a DDA cycle with one MS1 scan and 10 MS2 scans within 2 seconds. DDA typically 
yields thousands of analytes identifications. Unfortunately, irreproducibility and imprecision 
are fundamental to DDA’s design; if too many analytes co-elute and appear in a single MS1 
scan, then DDA stochastically samples only the most abundant ions and misses the rest16. 
This approach diminishes reproducibility and prevents the measurement of low-abundance 
peptides17. Additionally, to survey as many analytes as possible, DDA deliberately samples 
each ions only once or twice, preventing precise absolute quantification that requires 
multiple measurements per analyte. 
DDA is an acquisition strategy widely used in the so-called "discovery proteomics" because it 











Figure 5: DDA acquisition mode. 
 
 Selected Reaction Monitoring (SRM) and PRM (Parallel Reaction Monitoring). 
SRM and PRM are targeted mass spectrometry techniques that are emerging in the field of 
proteomics as a complement to untargeted shotgun methods. SRM and PRM are particularly 
useful when predetermined sets of proteins, such as those constituting cellular networks or 
sets of candidate biomarkers, need to be measured across multiple samples in a consistent, 
reproducible and quantitatively precise manner19. Instead of selecting the top n precursors 
in an MS1 scan for further fragmentation in MS2 scans, these methods select only 
precursors and fragments with the m/z and elution time that match a pre-specified analyte 
of interest. In MRM, for each MS1 scan, a subset of fragment ions is measured in the 
subsequent MS2 scan20, whereas in PRM, all of the fragment ions are measured21. In both, 
the same precursors are selected and fragmented multiple times to acquire more precise 
quantification of fewer peptides, compared with DDA22.  
 Data Indipendent Analysis (DIA). 
In DIA mode, for each cycle, the instrument focuses on a narrow mass window of precursors 
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window is then stepped across the entire mass range, systematically collecting MS/MS data 
from every mass and from all detected precursors. The most common method to generate 
DIA data is called SWATH (SequentialWindowed Acquisition of All Theoretical Fragment 
ions), in which the mass spectrometer divides the mass range into small mass windows.  
 
 
Figure 6: DIA acquisition mode. 
 
In SWATH, the mass analyzer cover 400-1200 m/z as an overall mass range and the mass 
spectrometer steps with 2-4seconds cycle time by precursor acquisition windows. During 
each cycle, the mass spectrometer thus fragments all precursors from the quadrupole 
isolation window (such as 475 – 500 m/z for 25 wide windows) and a complete, high 
accuracy fragment ion spectrum of all precursors selected in that isolation window is 
recorded. The same precursor isolation window is fragmented over and over at each cycle 
during the entire chromatographic separation, thus providing a time-resolved recording of 
the fragment ions of all the precursors that elute on the chromatography. The SWATH MS 
data consists therefore of highly multiplexed fragment ion maps that are deterministically 
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4 PROTEOMICS OF AUTOINFLAMMATORY DISEASES 
4.1  Introduction  
Proteomics is defined as the study of the globality of proteins, in their functional complexity. 
The term proteome was introduced by Wilkins23 to identify proteins (prote-) expressed by a 
genome (-oma). Knowledge of the sequence of the entire human genome is only the first 
step in understanding the functioning of the cellular machine at the molecular level; the 
proteome can therefore be seen as the end product of the process of DNA 
translation/transcription to proteins and is complementary to genomic information in 
understanding cellular mechanisms. 
 
 
Figure 7: Factors involved in determining the proteome complexity. 
 
The proteome is extremely complex, in fact there are many potential variability factors 







Innovative analytical methods for the study of low and high weight molecules involved in diseases. 
 
 
translational modifications, sub-cellular localization, mRNA translation efficiency, assembly 
of proteins with different compositions, Figure 7. 
The cellular proteome is a complex microcosm of structural and regulatory networks that 
requires continuous surveillance and modulation to meet cellular needs. It is therefore 
essential that the protein flow of the cell remains in equilibrium to ensure the correct 
functioning of the cells. Genetic alterations ranging from chromosome imbalance to 
oncogene activation can affect the speed and capacity of biogenesis and protein degradation 
systems, which often result in proteome imbalance. In a balanced proteome (Figure 8a), the 
level of protein production does not exceed the capacity of protein depletion systems. To 
achieve this balance, many factors contribute to protein generation or degradation. Events 
and cell states such as chromosomal imbalance, oncogenic activation and translation errors 
alter the proteome in ways that promote proteotoxic stress and lead to an imbalance in the 
proteome (Figure 8b). 
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Numerous biological processes are simultaneously  active in every living cell. Each of them 
includes synthetic, catalytic and regulatory functions that are almost always performed by 
proteins further organized into higher order structures and networks. For decades, the 
structures and functions of selected proteins have been studied using biochemical and 
biophysical methods. However, the properties and behavior of the proteome as an 
integrated system have remained largely unknown. Powerful mass spectrometry-based 
technologies provide informations on the composition, structure, function and control of the 
proteome, explaining the complex biological processes and phenotypes of a physiological 
and/or pathological state. Proteomics based on high-resolution mass spectrometry is 
suitable for the study of post-transdutional changes because leads to characteristic changes 
in mass and can be localized with the resolution of a single amino acid. 
To be successful, clinical proteomic projects must link observed phenotypes to modern 
molecular medicine through the analysis of complex proteoforms. Clinical phenotypes are 
affected by both familial inheritance (genotype) and environmental effects (that is, there can 
be differing molecular causes for the same underlying disease). 
The two principal approaches to identifying and characterizing proteins using mass 
spectrometry are the “bottom-up”, which analyze peptides by proteolytic digestion and 
“top-down”, which analyze intact proteins. 
Bottom-up proteomics is the most mature and most widely used approach for protein 
identification and characterization. The bottom-up approach provides an indirect 
measurement of proteins through peptides derived from proteolytic digestion of intact 
proteins. Intact proteins are digested into peptides prior to introduction into the mass 
spectrometer where they are then detected and fragmented24. 
Shotgun proteomics refers to a use of bottom-up proteomics techniques to study the whole 
proteins in a complex mixture, such as serum, urine, and cell lysates, etc. It utilizes HPLC in 
combination with mass spectrometry technology. The most distinctive feature of shotgun 
proteomics is that it enables identification and comparative quantification of a wide range of 
proteins at the same time with minimal protein separation needed. Protein mixtures are first 
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MS/MS analysis to identify the sequence of each peptide. The identified peptide sequences 
are compared with database, in searching for the corresponding protein identity25.  
Top-down proteomics can characterize intact proteins from complex biological systems. This 
approach routinely allows for nearly 100% sequence coverage and full characterization of 
proteoforms, the specific molecular form of the protein resulting from combinations of 
genetic variation, alternative splicing, and post-translational modifications. Fragmentation 
for tandem mass spectrometry is accomplished by electron-capture dissociation (ECD) or 
electron-transfer dissociation (ETD). The proteins are extracted from cell or tissue lysates, 
separated by either gel or LC, and directly analyzed by MS for a complete view of all 
proteoforms including those with PTMs and sequence variations26.  
Essentially two approaches are used for protein quantification : label free quantification and 
chemical or metabolic label. 
Label-free quantification is a method of determining the relative amount of proteins in two 
or more biological samples, but unlike other quantitative methods, it does not use a stable 
isotope for chemical binding and labeling of proteins. Label-free quantitative proteomics 
approach provides a powerful tool to resolve and identify thousands of proteins from a 
complex biological sample. In this approach, proteins are first digested with a protease into a 
peptide mixture, which is subsequently analyzed by tandem MS (MS/MS) and identified by 
database searching. Relative protein abundance is determined by either spectral counting or 
chromatographic peak intensity measurements. 
The label free approach is opposed by the label methods such as chemical labeling or 
metabolic labeling. Heavy stable isotope labels can be introduced in vivo by growing cells or 
even whole organisms in the presence of amino acids or nutrients carrying such stable 
isotopes. Metabolic labeling is often the preferred labeling technique, since incorporation 
occurs at the earliest possible moment in the sample preparation process, thereby 
minimizing the error in quantification. 
The advantage of chemical labeling over metabolic labeling is the possibility to label a wide 
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harvesting cells and subsequent purification of proteins. Chemical labeling is essentially 
based on similar mechanisms as metabolic labeling, except that the label is introduced into 
proteins or peptides by a chemical reaction. Alternatively, the heavy stable isotope label can 
be introduced into the peptide during an enzymatic reaction with heavy water (H2
18O). In all 
PhD experiments label free approach was carried out. 
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4.2  State of the art 
Autoinflammatory diseases are a group monogenic inflammatory conditions characterized 
by an early onset during childhood. Under the term “periodic fevers” are gathered some 
monogenic diseases characterized by periodic or recurrent episodes of systemic 
inflammation causing fever often associated with rash, serositis (peritonitis, pleuritis), 
lymphadenopathy, arthritis, and other clinical manifestations27. 
Most of these conditions are caused by mutations of genes regulating the activation of 
innate immunity leading to an unprovoked activation of inflammatory response28. A genetic 
defect is a modification of a gene by an event known as mutation. This mutation alters the 
function of the gene, which gives incorrect information to the organism giving rise to the 
disease. The most common autoinflammatory diseases are the so called monogenic 
recurrent fevers, namely: Familial Mediterranean Fever (FMF), TNF receptor-associated 
periodic syndrome (TRAPS) and mevalonate kinase deficiency/hyperimmunoglobulin D 
syndrome (MKD/HIDS). 
Figure 9 shows a simplified scheme of the pathogenesis of the main autoinflammatory 
syndromes. The mutated proteins are marked with an asterisk and green lettering denotes 












Figure 9: Scheme of the pathogenesis of the main autoinflammatory syndromes. 
 
In CAPS genetic diseases the mutation on the CIAS1 gene alters the production of a specific 
protein called Cryopyrin and affects its function. The mutated ASC protein stimulates the 
proinflammatory cytokinic response of IL-1β promoting the inflammatory process causing 
fever and inflammation in sick patients. 
Periodic cryopyrin-associated syndromes (CAPS) include a group of rare autoinflammatory 
diseases including Familial Autoinflammatory Cold Syndrome (FCAS), Muckle-Wells 
Syndrome (MWS) and Chronic Infantile Neurological Cutaneous Articular Skin Syndrome 
(CINCA), also known as neonatal onset multisystemic inflammatory disease (NOMID). These 
syndromes were initially described as distinct clinical entities despite some clinical 
similarities: patients often present with overlapping symptoms including fever, hives-like 
rashes (pseudo-orticaria) and joint involvement of varying severity associated with systemic 
inflammation. These three diseases exist on a continuum of severity: FCAS is the mildest 
condition, CINCA (NOMID) the most severe, and patients with MWS have an intermediate 
phenotype. Characterizations of these conditions at the molecular level have demonstrated 
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MEFV is the first gene mutated discovered in FMF patients, the mutation has a autosomal 
recessive inheritance and leads to a loss of function of the protein29,30. The gene encodes for 
Pyrin protein; Pyrin after activation forms a Pyrin-inflammasome that is able to process IL-1β 
independently from NLRP3. Recent studies showed that Pyrin can sense signal changes of 
cytoskeletal organization by bacterial toxins via RhoA. Toxins can inactivate RhoA and lead to 
actin depolymerization, in this manner pyrin senses bacterial infection and responds by 
nucleating an inflammasome. Mutated Pyrin forms substantially reduce the binding affinity 
to PKNs (serine/threonine protein kinases that phosphorylates pyrin) and thus escape from 
the inhibitory phosphorylation due to the link with the inhibitory 14.3.3 protein31,32. 
14-3-3 proteins are a family of conserved regulatory molecules that are expressed in 
all eukaryotic cells. 14-3-3 proteins have the ability to bind a multitude of functionally 
diverse signaling proteins, including kinases, phosphatases, and transmembrane receptors. 
More than 200 signaling proteins have been reported as 14-3-3 ligands. 
In patients with TRAPS, the mutation is a heterozygous mutation in TNFRSF1A which encode 
for the TNFR1 receptor. The result is a misfolded molecule that is retained in the 
endoplasmic reticulum and the consequent oxidative stress and defective autophagy 
represents a trigger for the production and the activation of pro-inflammatory cytokines. 
MKD is caused by biallelic loss-of-function mutations in the MVK gene, which encodes 
mevalonate kinase and is also linked to pyrin-inflammasome activation. The identification of 
the molecular defects associated to recurrent fevers sheds new lights in the pathogenesis of 
these conditions. However, the understanding of all the intracellular consequences 
secondary to the mutations of the genes involved is far to be completely achieved. A defect 
in MVK gene leads to RhoA inactivation and diminished PI3K (phosphoinositide 3-kinase) 
activity; this potentiates pyrin-inflammasome activation33,34. 
In the last few years, there has been a massive expansion of large-scale proteomic data that 
has facilitated the comprehension of the complexity of the intracellular communication and 
the identification of new markers of disease. Proteomics based on high-resolution mass 
spectrometry has maturated into attractive technology that allows the quantification of 
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Studying the monocytes of these patients using a quantitative proteomics we will try to 
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4.3  The aim of the project 
The diagnosis of autoinflammatory diseases is complex and often based on the exclusion of 
other diseases. The autoinflammatory diseases involve genetic mutations and malfunctions 
of the proteins encoded by genes. It is easy to understand how a proteomic analysis is of 
fundamental interest to understand the molecular mechanisms underlying genetic diseases 
but not only, the study of proteome also represents the hope to find biomarkers of disease 
that allow to predict the disease before the onset of symptoms. There are also some 
diseases that have symptoms very similar to the above mentioned diseases but whose 
genetic mutation is not yet known. The aim of this project is also to identify a protein 
pattern characteristic of each known disease and compare it with the proteomic analyses 
that will be carried out on samples of patients suffering from the still unknown diseases to 
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4.4  Sample Preparation 
Fifteen patients with FMF (5), TRAPS (5), and MKD (5) were evaluated and compared with 
Fifteen healthy donors (HDs). Disease activity of patients was evaluated at the moment of 
the sampling by considering clinical manifestations and laboratory tests including C-reactive 
protein (CPR) and serum amyloid A (SAA). Almost all patients were analyzed in a symptom-
free period and during an ongoing treatment. Patients with TRAPS and MKD were in 
treatment with Canakinumab (except Case No 14 and 15), patients with FMF were under 
colchicine treatment (except Case No 3),Table 1. The study was approved by the ethics 
board of G. Gaslini institute. 
 
Table 1: Patients 
ID Disease Mutation CPR (mg/dL) SAA (mg/L) Drug 
1 FMF M694V/M694V 1,82 145 Colchicine 
2 FMF M694V/V726A 1,16 26 Colchicine 
3 FMF M694V/V726A <0,46 15,3 None 
4 FMF M680I/V726A <0,46 14,2 Colchicine 
5 FMF M694V/M694V <0,46 4,2 Colchicine 
6 TRAPS C55Y <0,46 2,07 Canakinumab 
7 TRAPS C88Y <0,46 1,8 Canakinumab 
8 TRAPS C52Y <0,46 5,39 Canakinumab 
9 TRAPS T50M <0,46 9,94 Canakinumab 
10 TRAPS C55Y <0,46 3,86 Canakinumab 
11 MKD L265R/V377I <0,46 4,1 Canakinumab 
12 MKD C605insG/V377I 1,21 135 Canakinumab 
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14 MKD V310M/V377I 3,08 130 None 
15 MKD V377I omo <0,46 16,8 None 
 
Peripheral blood mononuclear cells (PBMCs) of patients and controls were isolated by 
gradient (Ficoll Hystpaque) and then purified with CD14 microbeads (Miltenyi Biotec) 
positive selection as indicated in the manual. Monocytes were analyzed in two different 
conditions: i) unstimulated after the sampling, ii) after LPS stimulation. This latter condition 
was used to test the responsiveness of monocytes to a TLR ligand in order to minimize the 
impact of disease activity and/or ongoing treatment. For this reason, monocytes were 
cultured for 4h in RPMI 1640 with 5% fetal calf serum in presence or absence of 
lipopolysaccharide (LPS, 100 ng/ml)38,39.  
Tryptophan fluorescence emission assay was used for protein quantification.  
Samples with protein amounts below 15 µg were discarded. The samples were processed 
following the method proposed in the literature, called in-Stage Tip40. The solubilization 
solvent, however, has been modified to obtain a better lysis of the sample. 
 
 
Figure 10: In Stage Tips sample preparation method. 
 
The protein pellet is solubilized in 25 µl of 2% (W/V) SDC, 10 mM TCEP, 40mM CAA, 100 mM 
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cycles of freezing the sample for 10 minutes at -20 °C and subsequent heating to 99 °C for 10 
minutes and sonication in an ultrasonic bath for 30 minutes. The sample was transferred 
into the tips containing 2 disks of a styrenedivinylbenzene resin modified with sulfonic acid 
groups to make it hydrophilic. The SDB-RPS disks are intended to purify the peptides and 
normalized their quantity in the different samples because the disk area is proportional to 
the amount of peptides retained, 16 gauge diameter is able to retain 7 µg peptides (Figure 
10). The lysate was diluted 1:2 with 10% (v/v) ACN, 25 mM Tris pH 8.5 and the peptide 
digested protein material with 0.5 µg lysine C and 0.5 µg trypsin at 37 °C overnight. The 
sample was diluted 1:2 because trypsin works well with up to 1% SCD and then acidified with 
100 µl trifluoroacetic acid (TFA) to block the enzyme action. The peptides are eluted with 60 
µl of 5% ammonium hydroxide and 80% acetonitrile (ACN) in water. The sample was 
lyophilized and taken back with 10 µl of 98% water (H2O), 2% ACN, 0.1% formic acid (AF). 
Considering that the containment capacity of each disc is 7 µg peptides, the final 
concentration of the sample injected by mass is approximately 1.4 µg/µl. 
 Tryptophan fluorescence emission assay.  
Protein concentrations were determined by tryptophan fluorescence emission at 350 nm 
using an excitation wavelength of 295 nm. 
Briefly, 1 μl of sample was solubilized in 200 μl of 8 M urea and 0.1 μg/μl tryptophan was 
used to build a standard calibration curve (0.25–1.5 μl).  
Protein concentration in samples was estimated considering the emission of 0.1 μg/μl 
tryptophan equivalent to the emission of 7 μg/μl of human protein extract, assuming that 
tryptophan accounts for 1.3% on the human protein amino acid composition, on average. In 
bottom-up proteomics, protein determination is the prerequisite for optimal protein 
digestion and the quantification of the generated peptides is important for mass-
spectrometry-based analysis. 
The direct quantitation of tryptophan by measuring its fluorescence is an easy, fast and 
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4.6  Mass spectrometer set up 
Peptides were analyzed by nano-UHPLC-MS/MS using an Ultimate 3000 RSLC with easy-
spray column (75 μm x 500 mm, 2 μm particle size, Thermo Scientific) and with a 180 minute 
non-linear gradient of 5-45 % solution B (80% acetonitrile, 20% H2O with 5% dimethyl 
sulfoxide and 0.1% formic acid) at a flow rate of 250 nl/min, Table 2. Solution A (98% H2O, 
2% acetonitrile with 0.1% formic acid) varies as a function of B solution. 
To reduce the counter pressure in the column the separation of peptides takes place at a 
temperature of 55 °C. 
Eluting peptides were analyzed using an Orbitrap Fusion Tribrid mass spectrometer (Thermo 
Scientific Instruments, Bremen, Germany). Orbitrap detection was used for both MS1 and 
MS2 measurements at resolving powers of 120000 and 30000 (at m/z 200), respectively 
(Table 3).  
Data-dependent MS/MS analysis was performed in top speed mode with a 3 sec. cycle time, 
during which precursors detected within the range of m/z 375−1500 were selected for 
activation in order of abundance. Quadrupole isolation with a 1.4 m/z isolation window was 
used, and dynamic exclusion was enabled for 45 s. Automatic gain control targets were 
2,5e5 for MS1 and 5e4 for MS2, with 50 and 45 ms maximum injection times, respectively.  
The signal intensity threshold for MS2 was 1e4. HCD was performed using 30% normalized 
collision energy. One microscan was used for both MS1 and MS2 events.  
 
Table 2: HPLC gradient. 




















The addition of DMSO in solvents has allowed the identification and quantification of 10% 
more proteins; increasing the nebulization of the analytes in the source. 
Table 3: MS parameters. 
Ion Source 
Ion Source Type Nano ESI 
Positive Ion (V) 2200 
Ion Transfer Tube(°C) 300 
 
Master Scan MS-OT 
Detector Type Orbitrap 
Resolution 120000 
Scan Range (m/z) 375-1500 
AGC Target 2.5e5 
Maximum Injection Time (ms) 50 
 
Dynamic Exclusion 
Exclude after n times 1 
Exclusion Duration (s) 45 
Intensity Threshold 1.0e4 











ddMS2 MS OT 
Isolation Mode 1.4 
Activation Type HCD 
HCD Energy (%) 30 
Detector IT 
Speed Rapid 
AGC Target 5.0e4 
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4.7  Data analysis 
MaxQuant software was used to process the raw data, setting a false discovery rate (FDR) of 
0.01 for the identification of proteins, peptides and PSM (peptide-spectrum match); 
moreover, a minimum length of six amino acids for peptide identification was required. 
Andromeda engine41, incorporated into MaxQuant software42, was used to search MS/MS 
spectra against the Uniprot human database. For protein digestion, allowing for cleavage N-
terminal to proline, trypsin was chosen as enzyme. Cysteine carbamidomethylation was 
selected as fixed modification, whereas acetylation protein N-terminal, oxidation (M) and 
deamidation (N, Q) have been selected as variable modifications. A tolerance of 7 ppm was 
set for the mass deviation of the precursor ions, while the maximum mass deviation for MS2 
events was 0.5 Da. 
Algorithm MaxLFQ43 was chosen for protein quantification, with the activated option ‘match 
between runs’ to reduce the number of the missing proteins. All bioinformatics analyses 
were done with the Perseus software of the MaxQuant computational platform. 
The Perseus software platform supports biological and biomedical researchers in 
interpreting protein quantification, interaction and post-translational modification data. 
Perseus contains a comprehensive portfolio of statistical tools for high-dimensional omics 
data analysis covering normalization, pattern recognition, time-series analysis, cross-omics 
comparisons and multiple-hypothesis testing. A machine learning module supports the 
classification and validation of patient groups for diagnosis and prognosis, and it also detects 











Figure 11: Data analysis scheme. 
Protein groups were filtered to require 70% valid values in at least one experimental group. 
The label-free intensities were expressed as base log2, and empty values were imputed with 
random numbers from a normal distribution for each column, to best simulate low 
abundance values close to noise level. For each group, a t-test with permutation-based FDR 
of 0.05 and a s0 of 0.1 was used.  
The Venn diagram of identified proteins was calculated using an online tool. A Student’s t-
test analysis (FDR of 0.05 and S0 of 0.1) was performed to characterize differences and 
reciprocal relationships between the two groups in each disease. The significant proteins 
were plotted using a Volcano plot. 
We also performed a Cytoscape analysis to identify molecular interaction pathways and 
biological functions of proteins founded in monocytes.  
Cytoscape is an open source software platform for visualizing molecular interaction 
networks and biological pathways and integrating these networks with annotations, gene 
expression profiles and other state data. Although Cytoscape was originally designed for 
biological research, now it is a general platform for complex network analysis and 
visualization. Cytoscape core distribution provides a basic set of features for data 
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called Plugins). Apps are available for network and molecular profiling analyses, new layouts, 
additional file format support, scripting, and connection with databases46. 
In order to study  modulated protein interaction networks STRING database was used in 
Cytoscape; the analysis was integrated with a DISEASES database query in order to highlight 
proteins already known to be related to each diseases and proteins not yet linked to the 
diseases. STRING provides a network view on functional protein associations, based on 
direct (physical) and indirect (functional) protein-protein interactions47. This tool uses both 
known and predicted interactions (derived from indirect evidences of gene co-occurrence, 
fusion events, co-expression and conserved neighborhood), to whom a confidence score is 
attributed by comparing to a reference set of trusted true associations (KEGG database). 
ClueGo and CluePedia plugins of Cytoscape were used to build a functionally grouped 
networks based on GO terms, Reactome, Kyoto Encyclopedia of Genes and Genomes and 
WikiPathways with terms as nodes linked based on their κ score level (≥0.3) . Only the most 
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4.8  Results  
The protein content of monocytes of patients and healthy donors, once isolated from 
peripheral blood, is analyzed and quantified by tandem mass spectrometry.  
For each disease (FMF, TRAPS, MKD), monocytes from patients were compared to healthy 
donors (HD) in two different conditions: i) un-stimulated monocytes, ii) LPS-stimulated 
monocytes. Each group consists of 5 biological replicates belonging to 5 different patients. 
Globally, at a peptide and protein false discovery rate (FDR) of 1%, we identified about 5000 
proteins, with an average of more than 4000 proteins per group. The numerical distribution 
of each experiment is reported through the Venn diagram, Figure 12. Through the Venn 
diagram we do not see the modulated proteins but the presence / absence of the proteins in 
the different experimental conditions. 
In unstimulated and LPS-stimulated FMF samples 4507 proteins are common among all 
conditions; 25 and 22 proteins are exclusive of LPS-stimulated and untreated FMF samples 
respectively.  
In unstimulated and LPS-stimulated TRAPS samples 4092 proteins are common among all 
conditions; 26 and 36 proteins are exclusive of LPS-stimulated and untreated TRAPS samples 
respectively. 
In unstimulated and LPS-stimulated MKD samples 4223 proteins are common among all 













Figure 12: Venn diagrams of unstimulated and LPS-stimulated FMF, TRAPS and MKD 
samples.  
 
As will be described later, the differences are associated for Gene Ontology to the disease 
and to specific processes of immune response.  
In Figure 13 for each disease the t-test was used to identify the significantly modulated 
proteins, comparing patients and healthy controls, for unstimulated (left panels) and LPS 
stimulated (right panels) cells. In the case of FMF the unstimulated cells modulated 115 
proteins while in the LPS-stimulated cells produced 99 proteins. Similarly for the TRAPS the 
proteins are 16 and 90 as well as for MKD are 36 and 415 in unstimulated and LPS-
stimulated cells, respectively. 
The T-test is a parametric statistical test with the aim of verifying whether the average value 
of a distribution deviates significantly from a certain reference value. 
The statistically significant proteins from T-test are highlighted in the Volcano Plot as black 
pellets. For more clarity please refer to the supplementary tables where for each statistically 
significant protein the value of the p-value and the T-test difference is reported. The Volcano 
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p-value and on the abscissae the logarithm of the fold-change between the two conditions. 
In this type of graph the lower values of p-value (corresponding to high significance) are 
higher. A protein is more modulated when it has a high ordinate value and a value very 












Figure 13: Volcano plots of untreated and LPS-treated patients versus untreated and LPS-
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In supplement tables 1-6 at the end of the thesis are reported the significantly modulated 
proteins. 
However, LPS treatment maximizes differences between up-regulated proteins in monocytes 
of HRF patients and HD, independently from the disease activity and/or ongoing treatments. 
The Tables below summarizing interesting proteins significantly modulated in FMF, TRAPS 
and MKD patients compared with healthy controls in monocytes untreated or treated with 
LPS. In red and blue are the proteins up and down regulated respectively. 
 
Table 4: Interesting modulated proteins in untreated and LPS-treated FMF patients. In red 
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Table 5: Interesting modulated proteins in untreated and LPS-treated TRAPS patients. In red 
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Table 6: Interesting modulated proteins in untreated and LPS-treated MKD patients. In red 
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In order to highlight the differences in protein expression the graphs in Figure 14 have been 
constructed. The chart on the ordinates shows the ratio between the intensities of the 
proteins present in the untreated monocytes of the patients and those present in the control 
and on the abscissae the ratio between the intensities of the proteins present in the LPS-
stimulated monocytes of the patients compared to healthy donors. 
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Dividing the graph into quadrants we can say that:  
 in the upper right quadrant, we find the up regulated proteins characteristic of the 
disease, independently from the stimulus, 
 in the lower left quadrant are the up regulated proteins in healthy controls, 
regardless of the stimulus. 
In this way it was possible to compare the LPS-treated and untreated samples by disease in a 
single graph because they were both normalized with healthy controls. 
In all pathologies diseases, several proteins known to be related to the disease have been 
found significantly modulated, confirming the method used.  
A Cytoscape analysis with ClueGo app using STRING and DISEASE database was performed to 
identify proteins interactions and to highlight proteins already related to autoinflammatory 
diseases. 
The figures below show the modulated proteins and their interactions for untreated and 
LPS-treated FMF, TRAPS and MKD diseases. 
In particular the Figure 15 shows the modulated proteins between LPS-treated FMF patients 
and LPS-treated healthy donors; the Figure 16 shows the modulated proteins between 
untreated FMF patients and untreated healthy donors; the Figure 18 shows the modulated 
proteins between LPS-treated TRAPS patients and LPS-treated healthy donors; the Figure 19 
shows the modulated proteins between untreated TRAPS patients and untreated healthy 
donors; the Figure 21 shows the modulated proteins between LPS-treated MKD patients and 
LPS-treated healthy donors; the Figure 22 shows the modulated proteins between untreated 
MKD patients and untreated healthy donors. 
The figures 15, 16, 18, 19, 21, 22 should be read as follows. 
The proteins represented with a circle are those known from literature, while those 
represented with a square are those not yet related to the diseases under examination. In 
red the proteins that are up regulated in the disease samples and in blue those up regulated 
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Figure 17, Figure 20, and Figure 23 show the most modulated pathways in FMF, TRAPS, MVK 
diseases respectively. The three figures have the following reading. The large circles 
represent the modulated pathways, while the small circles represent the significant proteins 
related to pathways. In red are the significant up-regulated proteins in patients and in blue 
are the significant up-regulated proteins in healthy donors. Pathways are also colored in 
proportion to the expression of the proteins that belong to them. The size of the circles 
depends on how many proteins belonging to the pathway have been quantified.  
To give an explanatory example in Figure 17 FasL pathway/HSP regulation correlates directly 
with four proteins FAF1, DAXX, RB1, TNF, of which only one is up-regulated FMF1 in healthy 
donors because it is blue in color, the other 3 are up-regulated in diseased samples. The 
pathway color is for ¾ red (3 out of 4 proteins are colored red) and ¼ is colored blue. The 
RAC1/PAK1/p38/MMP2 pathway correlates 8 proteins of which two are up-regulated blue in 
healthy control and six are up-regulated red in diseased samples; the percentage color of the 
pathway is the same as above but the size is larger because it correlates with a double 
number of proteins. The pathway Regulation of Microtubule Cytoskeleton correlates with 
three proteins, all of which are up-regulated in diseased samples and therefore its color is 
exclusively red.  
In FMF monocytes treated with LPS , Figure 14, pro-inflammatory cytokines such as IL1β and 
TNFα were found up-regulated; also MEFV and RhoA are differently modulated according to 
the literature31,48,49, in this case MEFV is up-regulated and RhoA down-regulated 
independently by the stimulus. Some proteins related to RhoA pathway are differently 
modulated such as Fibronectin (FN1), GNAQ, PTPN11 that is able to activate RhoA but after 
stimulation with LPS is down-regulated. PTPN11 is also able to regulate MAPKinase pathway 
and PI3K-Akt pathway. A very interesting result is the high expression of several proteins 
related to the type 1 interferon (IFN-1) pathway such as IFIT1, IFIT2, IFIT3, ISg15 all up-
regulted after LPS stimulation. Also cGAS (MB21D1) that regulate the IFN-1 production in up-











The pathway analysis, Figure 17 highlight the regulation of microtubule cytoskeleton 
differently regulated in FMF patients and different pathway correlated with cytokines. 
 
Figure 17: Modulated pathways in FMF disease. 
 
Figure 15:  Protein network in LPS-treated 
FMF patients. 
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From Figure 18 and Figure 19 it is interesting to see that in samples of FMF patients the 
proteins that most modulate between the unstimulated and PLS stimulated samples are 
OPTN related to autophagy and maintenance of the Golgi apparatus, ADAM17 related to 
leukocyte degranulation, LYN related to chemokine signaling pathway and leukocyte 
degranulation and UFC1 associated to an autosomal recessive disorder apparent soon after 
birth or in early infancy.  
Other significantly modulated proteins are involved in vesicle transport (ACTR1A, TPT1, 
NUP43), and MAP Kinase pathway (RAP1A, VAV1, CRK). 
 
 


















Figure 20: Modulated pathways in TRAPS disease. 
 
The MKD complexity is evident from the number of proteins and pathways involved, Figure 
21, Figure 22, and Figure 23. In fact both metabolic and inflammatory pathway results 
regulated in patients. Prenylation is found to be related to this disease and in fact several are 
the proteins linked to prenylation founded regulated in patients monocytes mevalonate 
kinase deficiency. Different regulated proteins are related to the fatty acid metabolism 
(CPT1A, CPT2, ECI1, HADHA, SLC25A1, HSD17B4, ACAA2), many are those related to the 
transport of vesicles (ACTR1A, LMAN2, VPS16, VPS33, VPS29, VPS18, CTSZ, VAMP7, AP3M1, 
COPA, COPB1, SEC23B, AP-A1, DYNC1H1), or at the mitochondrial function (QARS, TARS, 
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4.9  Discussion 
The study of the proteome of autoinflammatory diseases was carried out in collaboration 
with the pediatric and rheumatology clinical operating unit. 
My research work consisted in the development of a method ranging from sample 
preparation to data analysis for high-resolution mass spectrometry-based proteomics. We 
have identified modulated proteins in patients with FMF, TRAPS and MVK and the pathways 
most affected by the disease. The effort made was not only to find a method for sample 
preparation and mass spectrometry analysis but also to provide a sufficiently clear 
interpretation of the data to doctors and biologists.   
It was not possible to compare the different diseases with each other because the samples 
and mass spectrometer analysis were performed in different times and their comparison 
was deemed unreliable.  
From this consideration we then decided to introduce isotopic peptides that allow the 
comparison between analysis carried out at different times, as is already the case for 
metabolomics experiments. 
The point of arrival of my work is the starting point of the pediatric and rheumatology 
clinical operating unit; on the results obtained from my PhD project, colleagues will direct at 
least part of their future research work. The data will then be validated by colleagues 
through other types of analysis such as cytofluorimetric methods.  
It cannot be excluded that mass spectrometry can also be used for the validation of possible 
biomarkers with targeted methods such as MRM.  
For a completeness of writing below I report part of the conclusions that biologists and 
doctors have drawn from the data obtained during the project. I want to emphasize that this 
part was not done by me. 
In LPS-treated FMF monocytes, high expression of IL1β, TNFα and proteins related to the 
type 1 interferon pathway, such as IFIT1/2/3 and ISG15, recalls treatment targets of 
FMF50,51,52. The higher concentration of the IL-6-induced STAT3/CDK9 complex in LPS-treated 
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FMF monocytes, thus acting against the use of flavonoids as CDK9 inhibitors in FMF patients. 
However, an increased oxidative stress in FMF patients seems confirmed by the high 
concentration of the macrophage migration inhibitory factor (MIF) in untreated FMF 
monocytes53. 
In LPS-treated TRAPS monocytes, up-regulation of the shedding protein ADAM17 suggests 
an ineffective attempt to correct the well-known TNF receptor 1 shedding defect54. 
Moreover, the up-regulated amyloidogenic TTR recalls the highest prevalence of systemic 
amyloidosis in TRAPS patients55. Differently from FMF data, pyrin inflammasome is not up-
regulated but even inhibited by the up-regulated 14-3-3 protein theta, a well-known pyrin 
inhibitor.  
MKD is a metabolic autoinflammatory disease and showed a higher complexity of proteins 
regulation. Essentially, the significantly modulated pathways are involved in the 
intermediate cell metabolism, ubiquitination, intracellular trafficking, and inflammation. In 
particular, NEDD8, ZNRF2, FBXO6, LSM12 and RBCK1, also known as HOIL-1, mediate 
ubiquitination, and SEC61B, STX7, DCTN6, AP1G2, TUBB1, MYO5A, LMAN2, 
VPS16/29/33A and CPNE2 are linked to the intracellular trafficking regulation, both 
emerging pathways in autoinflammation56,57. On the other hand, up-regulated PTPN18 can 
bind PSTPIP1, even modestly un-regulated in untreated and LPS-treated MKD monocytes, 
whose mutations have been related to the well-known IL-1-mediated autoinflammatory 
pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome. Finally, the 
up-regulated CBX5, also known as haptoglobin 1 alpha, have been associated with several 
inflammatory disorders due to its ability to modulate the helper T-cell type 1 and 2 balance 
and antioxidant properties. Down-regulated proteins in the LPS-treated MKD monocytes are 
mainly related to the NFkB-mediated inflammatory response (NFKB1, TLR2/8, RAP2B and 
TRIM4), as well as DNA transcription and RNA nuclear export (CLNS1A, TOP2B, TARS and 
XPO1), maybe explain the reduced microRNA-mediated silencing complex activity of the 
mevalonate pathway58. These evidences recall the increased susceptibility to infections of 
MKD patients. Furthermore, several down-regulated proteins participate to the fatty acid 
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prenylation defects of small GTPases in MKD59,34. Finally, the modulated MT-CO2, MFN2, 
MTCH2, IDH3G, NDUFA9, VDAC1, ECHDC1 and SLC25A1/3 proteins confirmed previous 
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5 Establishing a Shareable Spectral MSMS Library and Accurate Mass 
Retention Time (AMRT) Database for Pediatric Metabolomics 
Analysis. 
5.1  Introduction 
Omics technologies aim to identify and quantify huge numbers of compounds extracted 
from complex matrices, most commonly being biological, plant or food‐based materials. MS 
methods can be tailored for compound classes by manipulating the source parameters, 
setting conditions on MS/MS triggers or manipulating the pre‐MS separation conditions. 
Alternatively, a completely untargeted approach may be used to provide unbiased profiling. 
Universally, quick MS/MS scan speeds benefit these analyses.  
Metabolomics is an emerging approach that allows the comprehensive study of the low 
molecular weight molecules within an organism60,61 despite that the first metabolomic 
approach dates back to 1506 when physician recognizes pathology on the basis of colors, 
smells and tastes of urine, Figure 24.  
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Metabolomics, the newest addition to the “omics” domain and the closest to the observed 
phenotype, reflects changes occurring at all molecular levels, as well as influences resulting 
from other internal and external factors.  
The metabolomic approaches are divided in untargeted, which includes metabolomic 
screening and fingerprinting and targeted. 
The targeted approach is normally applied on information obtained from the previous 
approaches, where they are some metabolites recognized as biologically relevant (e.g. 
potential biomarkers). 
It is applied to measure a set of metabolites defined or to answer a question specific 
biochemistry. 
Metabolic fingerprinting studies the metabolome according to a holistic approach and from 
a limited point of biological knowledge first. 
The experimental design is aimed at acquiring a large subset of metabolites (100–1,000s) 
followed by reading the data to define biological differences. For interpretation, univariate 
statistical analyzes or multivariate. This approach aims to discover new ways metabolic or 
biomarker (fishing expedition).  
The targeted approach is normally hypothesis-driven while the fingerprinting studies are 
question-driven; the metabolic screening is a compromise in fact it aims to determine a large 
set of compounds to the same metabolic class. 
The chosen approach will determine how to draw the experiments, prepare the samples and 
which analytical technique use. It is essential to plan the project and the experiments with 
statisticians, analytical chemists, biochemists and doctors to collect the correct number of 
samples and treat them in the most appropriate way to get as much information as possible. 
The metabolome is considered as a final output of genetic, epigenetic and non-genetic 
factors62. A positive diagnosis of a disease is followed by treatment using drugs produced on 
a large scale and administered at a standardized and universally accepted dosage. These 
conventional drugs are developed to treat general symptoms or the disease as determined 
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understand that due to, for example, genetics and a variety of other factors such as 
individual diet, habits, gender etc., not all diseases affect all individuals in the same manner63 
and neither do all individuals respond to treatment in the same way64. 
By comparing the metabolite profiles of two or more disease phenotypes, metabolomics can 
be applied to identify biomarkers related to the perturbation being investigated. These 
biomarkers can, in turn, be used to develop personalized prognostic, diagnostic, and 
treatment approaches, and can also be applied to the monitoring of disease progression, 
treatment efficacy, predisposition to drug-related side effects, and potential relapse3,65,66 .  
From a clinical point of view, the metabolomic approach has three important applications 
potential: 
 The first application, identifying the set of metabolites that discriminate between 
different groups of subjects, makes possible the metabolic description of a particular 
disease phenotype. The discriminating metabolites can therefore be identified as 
potential pathology biomarkers. Considering the close correlation between the 
metabolome and the phenotype, many expectations of metabolomics studies are 
aimed at defining early metabolic disturbances that occur even before their 
appearance symptoms of the disease, potentially offering a diagnostic tool early. 
 The second major application is the determination of predictive profiles of pathology 
which, applied to the general population, could allow the development of what is 
called "molecular epidemiology". 
 The third important clinical potential is related to the identification of individual 
metabolic characteristics they may be able to predict the efficacy and toxicity of a 
drug treatment according to what it is defined as “pharmaco-metabolomics” 67,68. 
The purpose is to identify measurable markers before therapeutic intervention that 
are able to predict the effect and / or toxicity that the drug will have on the 







Innovative analytical methods for the study of low and high weight molecules involved in diseases. 
 
 
To summarize the ultimate goal of personalized medicine is to enable clinicians to prescribe 
the right medicine to the right patient at the right time with maximum efficacy and minimal 








Chiara Lavarello, Ph.D. Thesis in Chemical Sciences and Technologies. 
 
 
5.2  State of the art 
High resolution mass spectrometry  is increasingly used instrument for metabolomics thanks 
to its high performances allowing the analysis of complex matrices and the detection of 
hundred metabolites69. 
Untargeted metabolomics usually involves comparing the metabolome of control and test 
groups to identify differences between their metabolite profiles. These metabolomic 
differences may be relevant to specific biological conditions. 
In an untargeted metabolomics workflow, analytical reproducibility and stringent data 
analysis are the keys to a successful experiment. High analytical reproducibility means that 
the data are a direct expression of biological variance, both the chromatographic separations 
and mass spectrometers must have high reproducibility to minimize analytical variation.  
Because untargeted metabolomics aims to be comprehensive, it is imperative that the 
analytical technologies perform the following functions:  
 cover a breadth of metabolites with diverse physico-chemical properties, 
 possess a large dynamic range to analyze the varying abundances of metabolites, 
 possess high resolution accurate mass capability to separate isobaric species, 
 perform HRAM MSn for compound identification and structural elucidation. 
There are typically four steps in an untargeted metabolomics experiment: 
1. Experimental design consists in separating the biological study into multiple analytical 
experiments and analyzing quality controls for accuracy and precision of results to 
ensure successful experimental design70. 
2. Sample preparation is a must when using mass spectrometry-based techniques. There 
are multiple techniques based on sample type, and there are entire methods for 
extracting specific classes of metabolites70,71. 
3. Analytical procedures. Small molecule compounds are chemically and structurally 
diverse, so the mass spectrometer must be combined with a separation technique to 
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specific metabolite classes may be discriminated against and not appear at their normal 
abundance. 
4. Data analysis. Huge amounts of complex raw data must be analyzed in a stringent 
manner to remove experimental artifacts. To accomplish this task, stringent statistical 
tools and software are required for accurate compound identification and quantitation. 
As endogenous metabolites are diverse in their physico-chemical properties, as well as 
varying in abundance, a true comprehensive metabolomics study will require orthogonal 
sample preparation and separation techniques. In reality, most experiments are not 
comprehensive and there is a bias towards certain classes of compounds. 
The mass spectrometer can also introduce bias into the study. Utilizing positive or negative 
ion mode can affect which compounds can be ionized and detected. It is always 
recommended to analyzed positive and negative ions to avoid this bias.   
Untargeted metabolomics calls for utilization of exact mass measurements of precursor and 
fragment ions to enable the true identification of metabolites, versus features72,73. High‐
resolution mass spectrometry and high scan speeds are critical to increasing the depth of 
coverage. The ability to search data with a narrow, 1–3 ppm mass tolerance and include 
spectral accuracy based on the mass and intensity of detected natural isotopes can be 
critical to properly identifying each species74. In addition, both fragmentation techniques, 
HCD and CID, have been shown to provide complementary structural information that may 
be used to better annotate metabolites. It is most common to perform metabolomics using 
DDA, although recent work has published results using data‐independent acquisition. While 
the dynamic range for quantitation of the DDA and DIA data was similar for the metabolites 
targeted, DIA may offer the possibility to identify more species with lower S/N, at the cost of 
more difficult deconvolution. 
The increased presence of Orbitrap‐based instruments in the metabolomics field, combined 
with the rise of advanced software, has led to universal databases75,76,77,78 akin to those 
developed by NIST for chemical ionization. mzCloud is a freely available MS/MS database 
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available79,80. ChemSpider offers an alternate search engine of freely sourced data with over 
26 million entries ranging from high to low mass error. 
However, one of the major bottlenecks of metabolomics is the identification process of 
compounds, that is necessary to draw any biological conclusion from untargeted 
metabolomics data81 . Data processing workflows incorporate several defined steps such as 
noise filtering, peak detection, peak deconvolution, retention time alignment and finally 
feature annotation. Feature annotation is performed by comparing an experimental mass 
measurement to a database of known metabolites in order to generate potential candidates. 
HRMS measurement alone is not sufficient to provide metabolite information, indeed, 
additional information such as fragmentation pattern data and their matching with 
reference fragmentation spectra are essential. Moreover, given the wide variety of 
chromatographic and mass spectrometric conditions that can be employed to generate 
metabolomic experiments, it is essential that established metabolomics laboratories 
implement fixed robust and reliable protocols that yield stable retention times82. 
Standardization in metabolomics is still an unmet need but many efforts have been made 
towards realizing this aim. In 2007, the Metabolomics Standards Initiative (MSI) defined the 
rules to  achieve a consistent communication regarding metabolite identification confidence, 
a level system has been proposed and discussed83, starting with unique features (level 5) 
followed by molecular formula prediction (level 4). Tentative structure identification (level 3) 
on the MS1 level can be performed by m/z database searching (PubChem and ChemSpider). 
For putative identification (level 2) on the MS2 level several databases of experimental 
fragmentation data are available online such as METLIN, the Human Metabolome Database 
(HMDB) and mzCloud. However, these databases have several drawbacks. Full usability often 
requires commercial software and, in addition, available MS2 spectra have been generated 
with specific instruments or settings, precluding the transfer to other equipment. 
Importantly, consistent mass accuracy, resolution, collision energy (CE) and fragmentation 
are needed to ensure comparability. For ideal matching and as part of a validated 
identification (level 1), the MS2 spectra of reference standards and samples should be 
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identification when a structure is confirmed with a minimum of two independent and 
orthogonal data from a pure reference standard under identical analytical conditions84. 
Moreover, not all known metabolites are covered by available spectral libraries. Therefore, 
an in-house library is of great value for enhanced metabolite identification, even though the 
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5.3  The aim of the project 
Metabolomics is a relatively new approach compared to other “-omics”. With the rapid 
development of analytical technology and increasing passion of precision medicine, 
metabolomics has been extensively trialed in both the clinical and research studies. The 
individual metabotype at the baseline is informative for predicting responses to drug 
therapy and personal susceptibility to diseases during the follow-up. Meanwhile, the 
different metabolic profiles between baseline and post-treatment could reveal novel 
mechanisms of drugs by integrating the altered metabolites with involved metabolic 
pathways. 
For understanding processes and mechanisms in biological systems, High Resolution Mass 
Spectrometry gains more and more importance, but it is necessary to improve the 
construction of a simple, robust and standardized method from sample preparation to an 
accurate metabolites identification. 
The main challenge in untargeted approaches is a reliable metabolite identification. 
The purpose of this work is to build, optimize and share a spectral MSMS library with 
Accurate Mass Retention Time (AMRT) databases, using metabolic standards (MSMLS, IROA 
Technologies, Bolton, MA, USA), selected for their involvement in key biological processes, in 
order to simplify a robust metabolite identification and the development of quantitative 
methods. 
The PhD thesis reports the analytical steps needed to build the database, which are easily 
usable also on new and different molecules, so that research groups can customize their 
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5.4  Chemicals 
Ammonium formate, acetonitrile, methanol and formic acid (LC-MS grade) were purchased 
from Sigma Aldrich Srl (Milan, Italy). Water was purified by reverse osmosis and filtrated 
through a Milli-Q purification system (Millipore, Milford, MA, USA).  
The library of metabolite standards (Mass of Standards Mass Spectrometry Metabolite, 
MSMLS) was purchased from IROA Technologies (Bolton, MA, USA).  
4 reverse phase and 4 HILIC columns were tested, Table 7. 
 
Table 7: Chromatographic columns. 
Name Stationary 
phase 





ACQUITY BEH C18 2.1 X 100  1.7 Waters S.p.A. 
Hypersil GOLD 
aQ 








C18 2.1 X 150 2.6 ThermoFisher 
Scientific 
ACQUITY BEH Amide 2.1 X 150 1.7 Waters S.p.A. 
Accucore Amide Amide 2.1 X 150 2.6 ThermoFisher 
Scientific 
SeQuant ZIC-pHILIC 2.1 X 150 5 Merck S.p.a. 
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5.5  Workflow 
This paragraph shows the steps to build the spectral library and the AMRT database. 
Subsequently each step will be explained in detail. 
 MSMS spectral library construction using mzVault software, 
 choice of chromatographic conditions (columns and mobile phases) by analyzing IROA 
spiked plasma samples, 
 AMRT database construction, 
 database validation on real neuroblastoma plasma and epileptic urine samples. 
For each molecule we obtain the accurate molecular mass, 24 fragmentation spectra at 
different energies (12 positive and 12 negative), the positive and negative best 











Figure 25: Steps to build the MSMS spectral library and the AMRT database. 
 
5.5.1 MSMS spectral library construction 
MSMLS contains over 634 unique small molecule compounds, provided at 5 µg per well, 
arranged in 7 polypropylene plates with alphanumeric assigned positions. Forty-two 
compounds were excluded from analyses: 5 of them were out of our defined mass range 
(70-1000 m/z) and 37 were duplicates. Compounds were dissolved using two different 
solutions (10% methanol for plates 1-5 and chloroform:methanol:water  1:1:0.3 for plates 6 
and 7) in order to obtain a 0.1 µg/µL concentration.  
LC-HRMS analysis was carried out using a Vanquish Horizon UHPLC system coupled to a Q-
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Milan, Italy).  Ionization was obtained using an Electrospray (ESI) source both in positive and 
negative mode.  
In order to build the MSMLS spectral library, the compounds, contained in the corresponding 
wells, were analyzed by flow injection analysis (FIA) using the ESI source coupled with 
isocratic mobile phase 60/40 ACN/H20, 0.2% FA, at a flow rate of 0.15 ml/min, for a run time 
of 0.5 min. These analytical conditions have been optimized on a tryptophan standard, 
prepared in the same way used for the library.  
The source parameters were chosen to gain the maximum signal with acceptable stability 
(CV<5%) Table 8  
 
Table 8: Easy Spray source parameters. 
Parameter Value 
sheath gas (u.a.) 30  
auxiliary gas (u.a.) 10 u.a. 
temperatura di auxiliary gas temperature (°C) 300 
capillary temperature (°C) 300 
spray voltage + (V) 4000 
Spray voltage – (V) 3000 
 
The molecular ion was selected and fragmented using 12 different collision energies from 10 
to 120 eV, with steps of 10 eV. Few compounds do not generate the molecular ion and 
therefore it has been considered, if present, its adduct. 
Data were acquired in MS1 Full Scan mode with a resolution of 70000, AGC 1e6, mass range 
70-1000 m/z and a maximum injection time of 200 ms followed by a PRM event with an 
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with a resolution 17500, AGC 5e5, maximum injection time of 60 ms and an isolation 
windows of 1.2 m/z.  
The fragmentation library was built using mzVault 2.1 (ThermoFisher Scientific, Milan, Italy). 
The best collision energy for each compound in positive and negative mode was also chosen 
applying the rule of maximal selectivity and structural information. 
5.5.2 Chromatographic conditions 
The challenge of metabolomics as already mentioned is to identify and quantify hundreds of 
small molecules with very different physical characteristics. The choice of chromatographic 
conditions such as chromatographic columns, mobile phases and duration of 
chromatographic runs is fundamental to the success of the analysis. 
50 µl of plasma from healthy donors are extracted with 150 µl of cold methanol (-20 °C), 
centrifuged at 14,000 rpm for 10 min and the supernatant is spiked with the 634 molecules 
of our interest. 
Several chromatographic conditions were tested using the pooled plasma samples the 
spiked with the metabolite library. In particular, 8 different chromatographic columns and 
two different mobile phases (as specified in Table 9) were tested.  The linear gradient for 
reversed phase columns started with 1% B and in 15 minutes increased up to 100% with a 
flow rate of 250 µl/min, then the columns were normalized for 5 minutes with 1% phase B. 
The linear gradient for HILIC columns started with 90% B and decrease to 30% B in 15 
minutes with a flow rate of 200 µl/min, the columns was then normalized with 90 % phase B 
for 9 min. Separately for each polarity the experiments were done in data‐dependent 
acquisition mode alternating MS and MS/MS experiments. A maximum of 5 MS/MS 
experiments were triggered per MS scan. The intensity threshold was set at 1.6e5 using an 
isolation window of 1.4 Da. The m/z values of signals already selected for MS/MS were put 
on an exclusion list for 20 s.  70000 and 17500 resolution, 1e6 and 1e5 AgC, 100 ms and 50 
maximum injection time were used for MS1 and MS2 scan respectively, Table 10. 
To choose the best conditions, chromatographic suitability criteria were applied: symmetry 
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s, max peak width 3.6 s. The conditions that yielded the best results were then used to 
annotate the RT by analyzing 9 mixtures composed by non-isobaric molecules in solvent and 
in plasma. 
 
Table 9: Chromatographic conditions. 
 SOLVENT A1 SOLVENT A2 SOLVENT B1 SOLVENT B2 
C18 BEH 
 
0.1% FA in H2O 0.1% FA in H2O 0.1% FA in MeOH 0.1% FA in MeCN 
C18 aQ 0.1% FA in H2O 0.1% FA in H2O 0.1% FA in MeOH 0.1% FA in MeCN 
C18 Accucore Polar 
 
0.1% FA in H2O 0.1% FA in H2O 0.1% FA in MeOH 0.1% FA in MeCN 
Hypersil GOLD CN 
 
0.1% FA in H2O 0.1% FA in H2O 0.1% FA in MeOH 0.1% FA in MeCN 
BEH Amide 1.7µm 
 
5 mM ammonium formate 
pH 2 
5 mM ammonium formate 
pH 8 
MeCN MeCN 
ZIC - pHILIC 5µm  
 
5 mM ammonium formate 
pH 2 





5 mM ammonium formate 
pH 2 





5 mM ammonium formate 
pH 2 




Table 10: Mass spectrometer set up. 
Master Scan MS-OT 
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Scan Range (m/z) 70-1000 
AGC Target 1.0e6 
Maximum Injection Time (ms) 100 
 
Dynamic Exclusion 
Exclude after n times 1 
Exclusion Duration (s) 20 
Intensity Threshold 1.6e5 
DDA Mode Cycle Time 
 
ddMS2 MS OT 
Isolation Mode 1.4 
Activation Type HCD 
HCD Energy (%) Stepped 30, 40, 50 
Detector OT 
Resolution 15000 
AGC Target 1.0e5 
Maximum Injection Time (ms) 50 
 
The chosen columns are summarized in Table 11. HILIC overcome the challenge of retaining 
and separating extremely polar compounds. HILIC are designed to retain metabolites that 
are too polar to be retained by RP chromatography. Amide columns facilitate the retention 








Chiara Lavarello, Ph.D. Thesis in Chemical Sciences and Technologies. 
 
 
Table 11: Chosen columns. 
  Particle Type Ligand Type pH range Pressure tollerance 
BEH Amide 1.7µm 
2.1 X 150 mm  
Ethylene Bridged Hybrid (BEH) Trifunctional Amide 2-11 1000 bar 
C18 BEH 1.7µm  
2.1 X 100 mm 
 
Ethylene Bridged  
Hybrid (BEH) 
C18 1-12 1240 bar 
 
5.5.3 AMRT database 
The 634 molecules belonging to the MSMLS library have been divided into 9 mixtures so that 
no isobar molecules are present in the same mixture. In the supplementary table 7 the 
column D indicates the mixture to which each molecule belongs. Each mixture has been 
analyzed under the previously selected chromatographic conditions. The mixtures have been 
acquired in data dependent using an inclusion list that allows to give a fragmentation priority 
to the molecules belonging to the mixture under examination. The retention times of each 
molecule on the RP and HILIC columns have been recorded and are shown supplementary 
table 7, column G and H respectively. 
5.5.4 Untargeted metabolomic analysis of pediatric plasma and urine 
samples 
To validate the MSMS spectral library and the AMRT database, experiments on the most two 
used biological fluids plasma and urine were made.  
Urine metabolomics has emerged as a prominent field for non-invasive biomarkers discovery 
that can detect subtle metabolic changes brought by a specific disease or therapeutic 
intervention. 
Urine is a sterile, transparent amber-colored fluid generated by the kidneys. The kidneys 
extract excess water, sugars and a variety of other soluble wastes from the bloodstream. 







Innovative analytical methods for the study of low and high weight molecules involved in diseases. 
 
 
drugs, drinks, endogenous waste metabolites, environmental contaminants and bacterial by-
products. 
Blood is composed of a cellular component including red and white blood cells and platelets, 
and a liquid carrier, named plasma. Plasma accounts for about 50–55% of blood volume. 
Comparing to plasma, serum is less viscous don't have fibrinogen, prothrombin and other 
clotting proteins. Serum contains a large number of substances including nutrients (such as 
lipids, carbohydrates and amino acids), proteins and peptides (such as globulins, albumins, 
lipoproteins, hormones and enzymes), electrolytes, organic wastes and many other small 
organic molecules dissolved in them. As a primary carrier of small molecules in the body, 
serum plays a crucial role in the transportation of dissolved gases, hormones, nutrients and 
metabolic wastes, it also assists in the regulation of the ion composition and pH of interstitial 
fluids, the stabilization of body temperature, the defense against toxins and pathogens and 
the restriction of fluid losses at injury sites. Since blood enter every tissue and every organ in 
the body, it acts as an important liquid highway for all the molecules secreted, excreted or 
discarded by different tissues in response to different physiological or pathological stresses. 
In urine and plasma samples we have performed all stages of a real experiment but finally we 
will focalize our attention on the leve1 metabolites identification. To test the database 43 
urine samples belong to epileptic pediatric patients treated with two different drugs plasma 
and 37 plasma samples belong to neuroblastoma patients at different stage disease have 
been sampled. 
50 µl of plasma/urine were extracted with 150 µl of cold methanol (-20 °C), centrifuged (4 °C) 
and, after protein precipitation, the supernatant was recovered.  
The analytical study design is summarized in Figure 25. 
Different strategies—at best in combination—are generally accepted: addition of internal 
standards (IS) into each analyzed sample; continuous measurement of system suitability tests 
(SST) over the whole analytical batch containing a defined number of metabolites ideally 
evenly distributed over the chromatographic run; and inclusion of QC pool samples prepared 
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importance of experimental design and QC samples in large-scale and MS-driven untargeted 
metabolomic studies of humans. Further, randomization of the samples at least for analysis is 
an important step in untargeted metabolomics to prevent technical/instrumental biases. 
 
Figure 26: Analytical study design. 
 Procedure blanks. 
In the first 3-5 runs the procedure blank was analyzed in MS1 acquisition mode because the 
most 20 intense ions from blank samples will be put in an exclusion mass list of identification 
method. So the most intense ions of blank samples will not be fragmented in the 
identification runs. 
 Plasma samples. 
8-10 plasma samples runs were performed to condition the columns. 
 Study pooled QC 
About 10 µl of each samples (depending on the experiment length)  was mixed together in a 
pool sample which is analyzed every 4 samples. The usefulness of the QC study pooled is to 
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analyses. Additionally, these samples will be used to filter out features that will have a 
CV>25%.  
 External pooled QC. 
External pooled QC is a mixtures of plasma or urine or serum of healthy donors which we 
have made in large quantities. This external pool is used in all our experiment and acquired 
every 8-10 samples. 
The usefulness of this pool is to be able to compare different analysis batch by normalizing 
them to the pool.  
 Samples. 
The samples were acquired in full scan mode in Orbitrap using 70000 resolution, 1e6 AcG 
and 100 as maximum injection time. 
 Identification runs on study pooled QC. 
To identify the metabolites, the plasma/urine were analyzed in fullScan-ddMS2 mode with 
fragmentation priority. 70000 and 17500 resolution, 1e6 and 2e5 AgC, 100 and 65 ms were 
used for MS1 and MS2 scan respectively. The loop count was set at 5, the m/z values of 
signals already selected for MS/MS were put on an exclusion list for 5 s. A maximum of 5 
MS/MS experiments were triggered per MS scan. The intensity threshold for triggering 
MS/MS was set at 1.6e5 using an isolation window of 1.4. If no further inclusion list entries 
are identified in a scan event will be selected other masses. A normalized stepped collision 
energy of 20, 40, 80 was used. 
With Skyline software22, inclusion lists have been created with a retention time range of +/- 
0.5 minutes around the retention time in scheduled mode; to each metabolite was assigned 
the best fragmentation energy obtained by manual review of the spectral library.  
Skyline is a freely-available and open source Windows client application for building Selected 
Reaction Monitoring (SRM) / Multiple Reaction Monitoring (MRM), Parallel Reaction 
Monitoring (PRM), Data Independent Acquisition (DIA/SWATH) and DDA with MS1 
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cutting-edge technologies for creating and iteratively refining targeted methods for large-
scale quantitative mass spectrometry studies in life sciences22. 
Compound Discoverer software ver. 3.1 (Thermo Fisher Scientific) was used for data 
processing including retention time alignment, unknown compound detection, compound 
grouping across all samples, prediction of elemental compositions for all compounds, filling 
gaps across all samples, and background subtraction (using blank samples).  Compound 
Discoverer was used, Mass List, Spectral Library (ddMS2), mzCloud (ddMS2) and ChemSpider 
(KEGG85, BioCyc86, HMD75 as database) were used to identify level 2 and 3 compounds. Level 
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5.6  Results 
Using mzVault, the spectral MSMS library of 530 molecules was build, the molecular ion or 
its adduct was ionized in positive and negative mode and was fragmented with 12 different 
energies. The library containing the list of compounds, the molecular ions and the 
fragmentation spectra will be share in a public format. The best energy for each compound 
was also recorded (G and H columns in the supplementary table 7). Some molecules 
belonging to the database, have significantly different best fragmentation energies from 
those commonly used in discovery experiments (I and J columns in the supplementary table 
7).   
16 chromatographic condition were tested, the two columns which allowed us to obtain the 
best results were: ACQUITY C18 BEH as mobile phases A 0.1%FA in H2O and B 0.1% FA in 
ACN and ACQUITY BEH Amide using in A 5mM ammonium formate in H2O pH3 and in B ACN.  
Using the established MSMS and chromatographic conditions (as describe in paragraph 
5.5.3) a total of 359 and 191 compounds were detected by reversed phase and HILIC 
columns respectively analyzed in both positive and negative polarities.  
Moreover, using our defined protocol, plasma and urine samples derived from patients were 
analyzed. 
A total of 132 and 124 level 1 compounds belonging to AMRT database were identified in 
plasma and urine samples and listed in the supplementary tables 7. Figure 26 and Figure 27 
(Venn diagram) shows the number of metabolites identified in plasma and urine respectively 
and highlights the importance of combining the two different columns and MS polarities in 











Figure 27: Plasma level 1 metabolites. 
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5.7  Discussion 
Untargeted metabolomic analysis is a powerful technique in that it allows the collection of 
data without pre-existing knowledge and it is thus very useful for several applications. One of 
the bottlenecks of the untargeted strategy is represented by chemical structure 
identification. Chromatographic conditions and analytical methods such as sample 
preparation steps, chromatographic conditions and instrument platforms have an impact on 
the results directly influencing the subset of metabolites selected. However, identification of 
metabolites is crucial for drawing the correct biological conclusions so one of the major 
efforts for laboratories that want to approach untargeted metabolomic is the standardization 
of operative protocols for analysis and workflows used to obtain a transparent and confident 
metabolite assignment. In this PhD project we have developed a standardized protocol to 
build a MSMS spectral library and retention time database. 
The in-house spectral MSMS library and the Accurate Mass Retention Time database can be 
used in small molecule identification software such as Compound Discoverer, MSDials88, 
XCMS and improve the identification phase allowing the level 1 identification of about 400 
metabolites. 
Moreover, for each molecule the choice of the best fragmentation energy for both positive 
and negative polarities allows the optimization of the fragmentation energy in clinical 
matabolomics experiments. Usually in discovery experiments a stepped energy of 30, 40, 50 
eV is used. However, our data suggests that for many molecules these energies are not 
optimal and could affect the identification of metabolites, especially in complex matrices 
such as plasma and urine. 
The validation analysis was performed on the most two common biological fluids, the level 1 
metabolites identified with CV<20% are about 1 hundred; the number is not so high, but it 
allows a solid core of identified metabolites. 
The number of level 2 metabolites in plasma and urine samples is about 400 but these are 







Chiara Lavarello, Ph.D. Thesis in Chemical Sciences and Technologies. 
 
 
This protocol might be also useful for those who want to approach metabolomic untargeted 
analysis in fact it constitutes a reliable basis for the identification of level 1 of about 400 
metabolites. 
On the other hand spectral MSMS library and the retention time database can also be used 
by software developers to training and testing retention time prediction software89,90. 
The spectral library is proving to be very useful in ongoing projects and will certainly need to 
be increased with other metabolites of biological interest. 
The first metabolites of which we will acquire fragmentation spectra and retention times will 
be drugs, of which we have already bought a library of 1280 drugs (LOPAC library of 
pharmacologically active compounds, Merck KGaA). LOPAC is biologically annotated 
collection of inhibitors, receptor ligands, pharma-developed tools, and covers all major drug 
target classes. 
The MSMS spectral library and the AMRT database represent the first brick to an accurate 











Improvements in technology have fueled the proliferation of omics applications. Omics is a 
wide domain involving specialized and high-throughput biotechnological methods, 
instruments and algorithms. These techniques are often used to measure and study complex 
biological systems and their interactions. The omics platforms (genomics, proteomics and 
metabolomics) offers a systematic assessment of the interactions between genetic 
variations, central metabolism and environmental exposures to explain the initiation and 
progression of a disease. It is understood that the causation in systems biology should 
determine how and why a process occurs in a certain way rather than identify separate 
molecular components. 
During the PhD project we have studied the proteome of autoinflammatory disease, most of 
these conditions are caused by mutations of genes regulating the activation of innate 
immunity leading to an unprovoked activation of inflammatory response. It was possible to 
identify and quantify thousands of proteins thanks to the development of a miniaturized 
sample preparation and the development of a mass spectrometry method suitable for the 
small quantities of starting material we had available. 
Some proteins already known in literature have been confirmed as significantly modulated 
and some proteins have been identified could be key points in the mechanism of 
autoinflammatory diseases.  
Mass spectrometry has once again proved to be a useful tool in the complex path of 
understanding the molecular mechanisms underlying diseases. 
Metabolomics is the omic science closest to explaining the phenotype of a disease and 
therefore most used in precision medicine. Metabolomics allows the identification of 
prognostic and diagnostic biomarkers of the diseases. The biggest challenge is identifying 
features with high accuracy degree. During the PhD project, about 600 molecules that play a 
fundamental role in the metabolic processes were chosen to be analyzed with level 1 
identification according to the MSI guidelines. The database thus created can be used in 
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Supplementary Table 1 
Protein names Gene names Student's  
T-test p-value  
Student's  
T-test Difference 
Translation initiation factor eIF-2B subunit delta EIF2B4 2,6491 -1,08 
BCL2/adenovirus E1B 19 kDa 
 protein-interacting protein 3-like 
BNIP3L 2,64253 -1,04628 
Proteasomal ubiquitin receptor ADRM1 ADRM1 3,42823 -1,45877 
Thromboxane-A synthase TBXAS1 2,14246 -2,65853 
Ubiquitin-protein ligase E3A UBE3A 2,34873 -1,01414 
Baculoviral IAP repeat-containing protein 1 NAIP 2,35951 -0,962915 
Exosome complex component CSL4 EXOSC1 3,25102 -1,94119 
von Willebrand factor A domain-containing protein 9 VWA9 3,21249 1,0017 
Myeloid-associated differentiation marker MYADM 2,46876 -0,901073 
COP9 signalosome complex subunit 1 GPS1 2,57068 -1,6512 
Actin beta ACTB 1,78203 4,23435 
Lactotransferrin LTF 1,97549 5,68489 
Serine/threonine-protein kinase MARK2 MARK2 2,1941 -1,57728 
3-phosphoinositide-dependent protein kinase 1 PDPK1 2,29002 -1,1278 
DNA (cytosine-5)-methyltransferase 3A DNMT3A 2,88017 -1,36095 
Translocation protein SEC62 SEC62 2,69098 -0,83733 
Protein transport protein Sec24C SEC24C 3,09638 -0,6466 
Sjoegren syndrome/scleroderma autoantigen 1 SSSCA1 2,66599 1,16753 
Cathelicidin antimicrobial peptide CAMP 2,11231 4,27064 
28S ribosomal protein S7, mitochondrial MRPS7 2,15092 -1,50467 
ORM1-like protein 3 ORMDL3 2,12002 -1,40518 
Actinin alpha 4 ACTN4 2,06711 -2,05933 
Transmembrane protein 205 TMEM205 2,42134 -2,26277 
Dynamin-1-like protein DNM1L 2,31057 -1,73744 
Histone acetyltransferase type B catalytic subunit HAT1 1,88924 -2,76738 
2-deoxynucleoside 5-phosphate N-hydrolase 1 DNPH1 2,31399 0,988897 
Syntaxin-6 STX6 2,06827 -2,33611 
Uncharacterized protein KIAA0513 KIAA0513 2,1456 -1,23255 











Thioredoxin domain-containing protein 12 TXNDC12 2,84474 0,747147 
Fibronectin FN1 3,87831 -2,59544 
Non-histone chromosomal protein HMG-14 HMGN1 2,56373 -0,967116 
Prosaposin PSAP 2,79447 0,875078 
Annexin A3 ANXA3 2,0623 5,45663 
Macrophage migration inhibitory factor MIF 2,60382 1,46934 
Leukosialin SPN 2,59416 2,01043 
High mobility group protein HMG-I/HMG-Y HMGA1 2,41716 -1,1831 
Diacylglycerol kinase alpha DGKA 2,87246 -1,53102 
Peroxiredoxin-6 PRDX6 2,77405 0,686326 
60S ribosomal protein L9 RPL9 3,02732 0,67707 
Prohibitin PHB 3,38393 0,576388 
Replication factor C subunit 5 RFC5 2,15914 -1,77835 
Cysteine--tRNA ligase, cytoplasmic CARS 3,65283 -1,31223 
RNA-binding protein 25 RBM25 3,0307 -0,811191 
Ras-related protein Rab-9° RAB9A 3,98751 -1,23249 
RNA polymerase II elongation factor ELL ELL 2,09464 -1,41141 
Methionine--tRNA ligase, cytoplasmic MARS 2,12011 -1,51632 
ATP synthase subunit e, mitochondrial ATP5I 2,46174 1,055 
40S ribosomal protein S15 RPS15 2,60154 -0,989971 
Histone H3.2 HIST2H3A 2,11215 -4,91382 
Mitochondrial 2-oxoglutarate/malate carrier protein SLC25A11 2,25039 -1,14861 
Sialic acid-binding Ig-like lectin 14 SIGLEC14 2,19903 -2,05611 
Heat shock protein 75 kDa, mitochondrial TRAP1 2,53508 -0,936696 
TAR DNA-binding protein 43 TARDBP 2,54596 -0,825465 
Eukaryotic translation initiation factor 4E-binding 
protein 1 
EIF4EBP1 3,06487 0,743391 
Inositol-tetrakisphosphate 1-kinase ITPK1 2,65068 1,03663 
Cullin-3 CUL3 2,89467 -2,51483 
Tubulin beta-2A chain TUBB2A 2,10634 -1,80102 
Nuclear transcription factor Y subunit gamma NFYC 2,71195 0,712255 
V-type proton ATPase subunit F ATP6V1F 2,17341 1,71373 
Putative coiled-coil-helix-coiled-coil-helix domain-
containing protein CHCHD2P9, mitochondrial 
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Ubiquitin-associated protein 2 UBAP2 2,17427 -1,44638 
Rootletin CROCC 2,96526 1,10605 
Vacuolar protein sorting-associated protein 53 
homolog 
VPS53 2,51984 -2,16291 
Rap1 GTPase-activating protein 2 RAP1GAP2 2,36566 1,31747 
Tetratricopeptide repeat protein 37 TTC37 2,12155 -2,16444 
Vacuolar protein sorting-associated protein 13C VPS13C 3,49152 -0,673022 
UPF0317 protein C14orf159, mitochondrial C14orf159 1,97671 -1,88973 
Coiled-coil domain-containing protein 91 CCDC91 3,14619 -2,12756 
Nitrilase homolog 1 NIT1 2,48105 -0,895555 
Copine-8 CPNE8 2,15429 -1,72138 
Cytokine receptor-like factor 3 CRLF3 2,42804 -0,981761 
LysM and putative peptidoglycan-binding domain-
containing protein 2 
LYSMD2 2,56517 1,33936 
Mitochondrial Rho GTPase 1 RHOT1 2,26671 1,64559 
Misshapen-like kinase 1 MINK1 2,36364 -1,95205 
Oxidation resistance protein 1 OXR1 2,4458 -1,16105 
Eukaryotic translation initiation factor 4E type 3 EIF4E3 2,06687 -1,74517 
Cyclic GMP-AMP synthase MB21D1 3,51982 -3,01569 
GTPase IMAP family member 8 GIMAP8 5,72817 -0,482056 
Cyclin-Y CCNY 2,32371 1,97999 
ATP-binding cassette sub-family F member 1 ABCF1 2,48835 -0,929731 
Retinol dehydrogenase 11 RDH11 2,10449 -1,42718 
Nuclear pore membrane glycoprotein 210 NUP210 3,86408 0,818427 
AP-3 complex subunit sigma-1 AP3S1 2,27 1,30312 
Protein YIPF5 YIPF5 4,20425 -1,07156 
Coiled-coil domain-containing protein 47 CCDC47 2,65329 -1,0721 
RalBP1-associated Eps domain-containing protein 1 REPS1 3,54157 1,00333 
Copine-2 CPNE2 2,45587 0,974257 
ERO1-like protein alpha ERO1L 3,15015 1,10495 
Zinc finger RNA-binding protein ZFR 3,03535 -1,48686 
Ubiquitin-conjugating enzyme E2 E2 UBE2E2 2,84301 4,58013 
Calcium and integrin-binding protein 1 CIB1 2,43848 -1,66321 
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RNA-binding protein 4 RBM4 3,14836 0,634053 
Sharpin SHARPIN 2,26113 -1,16509 
Phosducin-like protein 3 PDCL3 2,90454 1,1818 
Translation initiation factor IF-3, mitochondrial MTIF3 2,2022 1,54116 
MIP18 family protein FAM96A FAM96A 2,97977 1,25787 
Calcyclin-binding protein CACYBP 3,47277 -0,546935 
Integrator complex subunit 7 INTS7 2,47123 -1,96085 
Aurora kinase A-interacting protein AURKAIP1 2,54637 -0,819901 
Cell growth-regulating nucleolar protein LYAR 2,96601 -1,88782 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex assembly factor 4 
NDUFAF4 3,49299 -1,45721 
Core histone macro-H2A.2 H2AFY2 2,90307 1,70402 
Glyoxylate reductase/hydroxypyruvate reductase GRHPR 3,14723 0,703817 
Protein NipSnap homolog 3A NIPSNAP3A 2,5962 -1,38459 
U6 snRNA-associated Sm-like protein LSm7 LSM7 2,14617 1,48891 
Glucocorticoid modulatory element-binding protein 2 GMEB2 2,49792 -0,921182 
DNA helicase INO80 INO80 2,58241 -0,919009 
FAS-associated factor 1 FAF1 2,66964 0,754553 
Peptidyl-prolyl cis-trans isomerase E PPIE 3,13143 -0,697405 
Sialic acid-binding Ig-like lectin 9 SIGLEC9 2,52277 -1,3022 
WD repeat-containing protein 7 WDR7 4,03392 1,10474 
Myeloblastin PRTN3 2,21776 1,43862 
 
Supplementary Table 2 
Protein names Gene names Student's  
T-test p-value  
Student's  
T-test Difference 
Apolipoprotein C-II APOC2 2,65529 1,73212 
AP-2 complex subunit mu AP2M1 2,70471 -2,07333 
Ig kappa chain C region IGKV3-11 2,96108 -1,84914 
Transmembrane emp24 domain-containing protein 7 TMED7-
TICAM2 
3,15646 1,2845 
Killer cell lectin-like receptor subfamily F member 1 KLRF1 2,42047 4,14973 
Thromboxane-A synthase TBXAS1 2,34402 -1,54743 
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Basic leucine zipper  
and W2 domain-containing protein 1 
BZW1 3,07285 -3,00868 
Myeloid-associated differentiation marker MYADM 2,3412 -1,68624 
COP9 signalosome complex subunit 1 GPS1 2,65123 -1,78145 
G protein subunit beta 2 GNB2 2,54111 2,01711 
Protein FAM195B FAM195B 3,41629 -1,7937 
Lactotransferrin LTF 1,8043 4,34023 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-3 
GNB3 2,79654 1,91601 
2,5-phosphodiesterase 12 PDE12 2,60798 -1,04542 
Aminoacyl-tRNA synthetases WARS 3,12091 2,4317 
Spermatogenesis-defective protein 39 homolog VIPAS39 3,48995 -1,63996 
Translocating chain-associated membrane protein 1 TRAM1 2,66561 -0,725739 
REST corepressor 1 RCOR1 2,00124 -2,87949 
Cytochrome B5 type B CYB5B 2,12077 -1,56355 
Myelin basic protein MBP 1,91818 -1,93226 
ATP-dependent RNA helicase DDX39A DDX39A 2,85283 -0,690964 
Insulin-like growth factor 2 mRNA-binding protein 3 IGF2BP3 2,01345 -2,89959 
Inhibitor of nuclear factor kappa-B kinase subunit beta IKBKB 3,013 -0,974699 
Cytochrome b-c1 complex subunit 8 UQCRQ 2,71608 -0,836841 
Histone H2B type 1-K HIST1H2BK 2,13071 4,77234 
Mitochondrial import receptor subunit TOM70 TOMM70A 2,84649 -0,732833 
NADH dehydrogenase [ubiquinone]  
1 alpha subcomplex subunit 3 
NDUFA3 2,43581 4,07581 
L-lactate dehydrogenase A chain LDHA 3,77584 0,746957 
Carbonic anhydrase 2 CA2 2,22256 -2,72336 
Tumor necrosis factor TNF 2,10769 2,12428 
Ubiquitin-like protein ISG15 ISG15 2,30345 2,85696 
Retinoblastoma-associated protein RB1 2,19513 -2,1079 
Epoxide hydrolase 1 EPHX1 2,82814 -1,09211 
Beta-glucuronidase GUSB 2,20811 1,2849 
Neutrophil elastase ELANE 2,1428 1,29188 
Interferon-induced protein with tetratricopeptide 
repeats 1 
IFIT1 1,88922 2,04699 
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60S ribosomal protein L35a RPL35A 2,95199 3,69147 
Tumor necrosis factor receptor superfamily member 
1B 
TNFRSF1B 3,53611 1,02287 
Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial 
SDHB 3,68361 -0,970757 
Oxysterol-binding protein 1 OSBP 2,47088 -0,857971 
Immunoglobulin alpha Fc receptor FCAR 1,86006 -2,38474 
Transcriptional repressor protein YY1 YY1 2,45033 -1,29518 
Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 2,72729 -0,716925 
SHC-transforming protein 1 SHC1 2,88778 -0,660619 
Enoyl-CoA hydratase, mitochondrial ECHS1 3,98197 0,886471 
ATP synthase subunit gamma, mitochondrial ATP5C1 2,45458 3,61616 
Signal transducer and activator of transcription 3 STAT3 2,69252 -1,61647 
Guanine nucleotide-binding protein G(q) subunit alpha GNAQ 3,18343 -1,22688 
Cyclin-dependent kinase 9 CDK9 3,08943 -1,72175 
Signal transducer and activator of transcription 5B STAT5B 2,53191 -1,12713 
Pterin-4-alpha-carbinolamine dehydratase PCBD1 2,61119 0,791427 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit 
PPP1CA 3,06993 0,90153 
U6 snRNA-associated Sm-like protein LSm6 LSM6 1,88535 2,34564 
40S ribosomal protein S15 RPS15 2,58079 -1,33849 
SUMO-conjugating enzyme UBC9 Ube2i 3,88061 -2,33522 
Signal peptidase complex catalytic subunit SEC11A SEC11A 2,88991 -1,23157 
Neutrophil gelatinase-associated lipocalin LCN2 1,85332 3,75308 
Tyrosine-protein phosphatase non-receptor type 11 PTPN11 2,86577 -0,697657 
Quinone oxidoreductase CRYZ 2,82319 -2,84019 
Mitochondrial-processing peptidase subunit alpha PMPCA 2,40649 -1,27734 
TAR DNA-binding protein 43 TARDBP 3,80335 -1,02279 
Cytoskeleton-associated protein 5 CKAP5 2,77314 -0,818856 
Putative heat shock protein HSP 90-alpha A4 HSP90AA4P 3,18752 2,13964 
BRO1 domain-containing protein BROX BROX 2,05345 -1,40511 
Microtubule-associated protein 1S MAP1S 2,9133 -1,2984 
Type-1 angiotensin II receptor-associated protein AGTRAP 1,98753 -1,59994 
UPF0317 protein C14orf159, mitochondrial C14orf159 1,91081 -3,06433 
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Putative phospholipase B-like 2 PLBD2 2,57368 -1,352 
Tudor domain-containing protein 7 TDRD7 1,9284 -2,67805 
Splicing factor U2AF 26 kDa subunit U2AF1L4 2,29238 2,59262 
Nuclear pore complex protein Nup133 NUP133 2,82081 -1,76479 
Ubiquitin carboxyl-terminal hydrolase 7 USP7 3,38129 -1,2865 
MOB kinase activator 3A MOB3A 2,52959 1,19402 
TNFAIP3-interacting protein 3 TNIP3 2,22684 1,54706 
Retinoid-binding protein 7 RBP7 2,00695 -1,99031 
Sorting nexin-18 SNX18 3,35005 -0,862465 
Calcineurin B homologous protein 1 CHP1 3,56584 -1,433 
Gamma-soluble NSF attachment protein NAPG 2,17734 -1,61833 
Death-inducer obliterator 1 DIDO1 2,5816 -1,03425 
Protein PBDC1 PBDC1 2,66488 -1,00433 
UBX domain-containing protein 6 UBXN6 2,36709 -1,66088 
Rab3 GTPase-activating protein non-catalytic subunit RAB3GAP2 2,63818 -1,61327 
Rab GTPase-binding effector protein 2 RABEP2 2,22598 -1,54912 
Complement component C1q receptor CD93 2,6965 -1,76187 
39S ribosomal protein L17, mitochondrial MRPL17 5,41162 -0,887653 
Structural maintenance of chromosomes protein 4 SMC4 2,22263 -1,35577 
CKLF-like MARVEL transmembrane domain-containing 
protein 6 
CMTM6 3,1136 -1,45964 
ER membrane protein complex subunit 3 EMC3 2,91134 -1,45108 
Protein RCC2 RCC2 3,3307 0,539761 
COMM domain-containing protein 3 COMMD3 2,83432 1,0291 
Death domain-associated protein 6 DAXX 2,32283 -1,55871 
Ragulator complex protein LAMTOR2 LAMTOR2 2,78285 1,85818 
WW domain-binding protein 11 WBP11 2,1449 -1,45081 
ARF GTPase-activating protein GIT1 GIT1 2,76892 -0,881892 
60S ribosomal protein L36 RPL36 3,10071 -1,50514 
Mitochondrial carrier homolog 2 MTCH2 3,62523 -1,69682 
 
Supplementary Table 3 
Protein names Gene names Student's T-test  
p-value (-log) 
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U4/U6.U5 tri-snRNP-associated protein 2 USP39 4,64476 -3,37603 
Beta-hexosaminidase HEXA 4,36552 -4,00728 
Inhibitor of nuclear factor kappa-B kinase subunit beta IKBKB 3,78714 -2,44653 
Glutaredoxin-3 GLRX3 4,24581 -1,35854 
Transthyretin TTR 4,71492 2,5282 
Tyrosine-protein kinase Lyn LYN 3,1506 4,66983 
Ubiquitin-conjugating enzyme E2 K UBE2K 4,66944 -3,01738 
Eukaryotic translation initiation factor 3 subunit M EIF3M 3,98755 3,2244 
Parkinson disease 7 domain-containing protein 1 PDDC1 4,19438 -2,06145 
Optineurin OPTN 4,89887 4,25239 
Type I inositol 3,4-bisphosphate 4-phosphatase INPP4A 3,67887 -2,00061 
39S ribosomal protein L39, mitochondrial MRPL39 4,20496 1,66681 
Peptidyl-prolyl cis-trans isomerase E PPIE 3,66788 -2,80125 
UPF0568 protein C14orf166 C14orf166 5,11778 -3,80364 
Ubiquitin-fold modifier-conjugating enzyme 1 UFC1 3,4539 -3,37135 
 
Supplementary Table 4 
Protein names Gene names Student's  
T-test p-value  
Student's T-test  
Difference 
Acyl-coenzyme A thioesterase 1 ACOT1 2,91761 1,8944 
Killer cell lectin-like receptor subfamily F member 1 KLRF1 2,35408 2,78495 
Zinc finger Ran-binding domain-containing protein 2 ZRANB2 2,92689 2,29108 
Ubiquitin-like modifier-activating enzyme 6 UBA6 2,34883 -2,60249 
Phosphoglycolate phosphatase PGP 3,87107 -1,19608 
GTP-binding protein Rheb RHEB 3,06775 -1,81305 
Protein PRRC2C PRRC2C 2,8109 0,757051 
ATP synthase F1 subunit beta ATP5B 3,34007 -2,09055 
Serine/threonine-protein phosphatase PPP4C 2,37124 1,35351 
Serine/arginine-rich splicing factor 2 SRSF2 5,07821 0,553397 
Sulfatase-modifying factor 2 SUMF2 2,50839 0,993273 
Lon protease homolog, mitochondrial LONP1 2,22189 -2,56644 
Transcription initiation factor TFIID subunit 4 TAF4 2,52059 0,902915 
Importin-5 IPO5 3,58239 -2,49514 
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Syntaxin-10 STX10 2,39669 -1,44128 
DnaJ homolog subfamily C member 13 DNAJC13 2,1122 -2,3428 
Acyl-protein thioesterase 2 LYPLA2 2,1156 -1,79507 
Apoptosis-inducing factor 1, mitochondrial AIFM1 2,31319 -1,21197 
Transthyretin TTR 2,17034 2,11562 
Superoxide dismutase [Mn], mitochondrial SOD2 3,47564 -0,795899 
60S acidic ribosomal protein P2 RPLP2 2,24316 -1,28098 
Uroporphyrinogen decarboxylase UROD 3,79867 0,718335 
Beta-hexosaminidase subunit beta HEXB 2,85845 -0,943622 
Histone H2A.V H2AFV 3,2165 -0,997572 
Prolyl 4-hydroxylase subunit alpha-1 P4HA1 3,20409 0,991196 
Proto-oncogene vav VAV1 2,52521 -2,42122 
Ganglioside GM2 activator GM2A 2,90487 -3,32058 
60S ribosomal protein L35a RPL35A 2,02909 -2,83904 
Oxysterol-binding protein 1 OSBP 2,92113 1,26053 
DNA replication licensing factor MCM3 MCM3 2,76898 -1,55605 
14-3-3 protein theta YWHAQ 4,92329 1,3736 
Proteasome subunit beta type PSM8 3,48298 -0,942297 
Signal transducer and activator of transcription 3 STAT3 2,54145 -1,81738 
G protein-coupled receptor kinase 6 GRK6 3,42739 1,3553 
Adapter molecule crk CRK 2,61655 2,1844 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A 
STT3A 2,26965 
-2,68238 
Signal recognition particle 9 kDa protein SRP9 2,51648 1,1249 
Rap1 GTPase-GDP dissociation stimulator 1 RAP1GDS1 3,31793 0,695963 
Arginine--tRNA ligase, cytoplasmic RARS 4,44209 -1,27305 
Adenosine kinase ADK 2,21462 1,47635 
6.8 kDa mitochondrial proteolipid MP68 2,5083 2,93227 
Alpha-centractin ACTR1A 2,40034 -1,12017 
Lysozyme C LYZ 2,97255 -0,677104 
Ras-related protein Rap-1A RAP1A 3,41596 1,57156 
40S ribosomal protein S15 RPS15 3,55048 -4,64983 
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Tumor necrosis factor alpha-induced protein 2 TNFAIP2 2,08198 -2,86997 
Serine/arginine-rich splicing factor 11 SRSF11 3,07982 0,768003 
Serine/arginine-rich splicing factor 4 SRSF4 3,80635 0,766953 
Syntaxin-5 STX5 3,04753 0,905947 
26S proteasome non-ATPase regulatory subunit 2 PSMD2 4,24552 0,847585 
Serine/arginine-rich splicing factor 6 SRSF6 4,02532 0,769634 
Voltage-gated potassium channel subunit beta-2 KCNAB2 3,46974 -1,43573 
Cold-inducible RNA-binding protein CIRBP 2,74965 1,03243 
Splicing factor 3A subunit 1 SF3A1 3,87414 0,572037 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 5 
NDUFA5 2,78074 
-1,08153 
Putative oxidoreductase GLYR1 GLYR1 3,1385 0,765809 
Torsin-1A-interacting protein 1 TOR1AIP1 3,22079 0,621812 
Ubiquitin-associated protein 2 UBAP2 3,14002 0,946587 
Aftiphilin AFTPH 2,29981 1,27546 
Protein unc-13 homolog D UNC13D 2,71693 -0,935266 
COMM domain-containing protein 1 COMMD1 2,60889 -1,30781 
Nucleoporin Nup43 NUP43 3,12088 -1,54425 
TBC1 domain family member 15 TBC1D15 2,67981 1,16709 




TBC1 domain family member 5 TBC1D5 2,07304 -2,53172 
La-related protein 4B LARP4B 2,1023 -1,80506 
Probable ubiquitin carboxyl-terminal hydrolase FAF-X USP9X 4,08315 0,908494 
Protein YIPF5 YIPF5 3,19344 0,935504 
Mediator of RNA polymerase II transcription subunit 8 MED8 3,09076 1,09395 
MMS19 nucleotide excision repair protein homolog MMS19 2,19116 1,76638 
Protein NipSnap homolog 1 NIPSNAP1 2,62543 1,20919 
Serine/threonine-protein phosphatase CPPED1 CPPED1 2,96519 1,12858 
Rho GTPase-activating protein 9 ARHGAP9 4,16595 0,576696 
RNMT-activating mini protein FAM103A1 3,08062 0,949156 
N-terminal Xaa-Pro-Lys N-methyltransferase 1 NTMT1 2,88891 0,713439 
Splicing factor 3B subunit 5 SF3B5 3,47688 0,699482 
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Protein phosphatase 1 regulatory subunit 12C PPP1R12C 2,7828 0,802731 
GTP-binding protein SAR1a SAR1A 2,35959 1,43886 




Myoferlin MYOF 2,45846 -2,84924 




Zinc finger protein 330 ZNF330 2,52607 0,902349 
Hypoxia up-regulated protein 1 HYOU1 3,22441 -1,1079 
Transforming acidic coiled-coil-containing protein 3 TACC3 3,13558 1,40283 
Cytoplasmic dynein 1 light intermediate chain 1 DYNC1LI1 2,89763 -0,883852 
 
Supplementary Table 5 




A-kinase anchor protein 9 AKAP9 5,09991 -5,45275 
COMM domain-containing protein 4 COMMD4 3,28256 1,655 
von Willebrand factor A domain-containing protein 8 VWA8 3,1464 4,5966 
Heat shock protein family A member 8 HSPA8 3,11882 -2,77979 
HEAT repeat-containing protein 5A HEATR5A 5,3754 -4,19927 
Transmembrane and coiled-coil domain-containing 
protein 1 
TMCO1 2,71126 2,52264 
Ras-related protein Rab-4B RAB4B 3,39498 3,42834 
Fructose-1,6-bisphosphatase isozyme 2 FBP2 3,98947 -2,4602 
Transthyretin TTR 2,97015 -4,66502 
Anion exchange protein 2 SLC4A2 3,86877 -1,61614 
Spermidine synthase SRM 2,71081 -3,37023 
High mobility group nucleosome-binding domain-
containing protein 5 
HMGN5 3,20722 -2,36694 
Aminoacylase-1 ACY1 4,24728 -1,58658 
T-lymphoma invasion and metastasis-inducing protein 
1 
TIAM1 4,06037 -2,40614 
Myotubularin-related protein 3 MTMR3 2,69437 -2,73138 
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Spectrin alpha chain, non-erythrocytic 1 SPTAN1 2,76857 -2,80785 
Protein RRP5 homolog PDCD11 4,82902 2,97891 
Rootletin CROCC 5,55965 -5,07579 
Ninein NIN 7,24404 7,13879 
Tetratricopeptide repeat protein 9C TTC9C 3,83862 -3,18524 
Mitochondrial import inner membrane translocase 
subunit TIM14 
DNAJC19 3,04649 -3,09963 
Proteasome subunit beta type-7 PSMB7 3,33627 3,04137 
CD180 antigen CD180 3,74148 -3,34947 
M-phase phosphoprotein 8 MPHOSPH8 2,88289 2,43691 
Ubiquitin-like protein 5 UBL5 4,15996 3,42452 
Mitochondrial fission factor MFF 2,83858 2,37847 
Kinesin-like protein KIF13A KIF13A 2,95261 -3,54405 
Olfactory receptor 10A2 OR10A2 2,84901 -2,22888 
Conserved oligomeric Golgi complex subunit 4 COG4 2,87489 3,17967 
Phosphopantothenate--cysteine ligase PPCS 3,81922 -4,05984 
Histidine triad nucleotide-binding protein 3 HINT3 3,14403 -2,48642 
3-oxoacyl-[acyl-carrier-protein]synthase,  
mitochondrial 
OXSM 2,95555 -1,79409 
Protocadherin beta-15 PCDHB15 6,76271 5,59694 
General transcription factor 3C polypeptide 5 GTF3C5 2,95287 -1,7429 
 
Supplementary Table 6 




40S ribosomal protein S9 RPS9 3,6641 -1,56307 
Proteasome subunit alpha type PSMA2 1,98229 -0,758658 
Zinc finger protein 787 ZNF787 2,89637 1,0644 
40S ribosomal protein S24 RPS24 2,43325 -1,99903 
Clathrin heavy chain CLTC 3,06215 -0,871793 
GMP reductase GMPR2 2,85874 -0,977707 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial 
NDUFA10 2,2165 
-1,33103 
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Selenoprotein H C11orf31 3,29106 0,445317 
Proteasome activator complex subunit 2 PSME2 1,73527 0,931124 




Isovaleryl-CoA dehydrogenase, mitochondrial IVD 1,72859 -1,19169 
Integrin-linked protein kinase ILK 2,62889 -0,740769 
Sulfotransferase SULT1A4 2,26674 -1,4465 




Serine/arginine-rich splicing factor 7 SRSF7 2,86164 0,583411 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
DDOST 2,2896 
-1,07467 
DNA-directed RNA polymerase POLR2A 3,52349 -1,16738 
Thromboxane-A synthase TBXAS1 3,55787 -2,35376 
Fatty acid synthase FASN 1,9973 -1,56089 
Shootin-1 KIAA1598 2,02041 0,883891 
Aconitate hydratase, mitochondrial ACO2 2,64385 -0,568282 
Small ubiquitin-related modifier 3 SUMO3 1,61329 1,95791 




Unconventional myosin-Ig MYO1G 2,56182 -0,850527 
Polyadenylate-binding protein PABPC4 3,38119 -1,486 
Branched-chain-amino-acid aminotransferase BCAT2 1,91725 -1,76094 
Septin-11 11-set 1,72841 -1,04883 
Annexin ANXA6 2,49616 -0,943773 
Protein PRRC2C PRRC2C 2,91316 0,74127 
Casein kinase II subunit alpha CSNK2A1 2,93641 -0,547729 
Complement receptor type 1 CR1 2,32872 -2,04296 





Protein transport protein Sec23A SEC23A 2,95576 -1,05487 
2,5-phosphodiesterase 12 PDE12 2,046 -0,666538 
CAD protein CAD 2,90084 -1,85107 
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catalytic subunit delta isoform 
Eukaryotic translation initiation factor 2A EIF2A 2,45773 0,625928 
Translocation protein SEC62 SEC62 2,18751 1,92992 
Aminoacyl-tRNA synthetases WARS 2,76214 3,00623 
Sp110 nuclear body protein SP110 1,51842 2,91582 
AMP deaminase 2 AMPD2 2,13904 0,600659 
Methyltransferase-like protein 7A METTL7A 2,63543 -2,1536 
RNA-binding protein with serine-rich domain 1 RNPS1 2,85446 0,561779 
Beta-hexosaminidase HEXA 1,95113 -2,08827 
Proteasome-associated protein ECM29 homolog KIAA0368 1,70311 -1,46049 
REST corepressor 1 RCOR1 2,03264 0,763764 
Ubiquitin thioesterase OTUB1 OTUB1 2,1114 -0,781033 
Tubulin-specific chaperone D TBCD 1,91019 -1,46345 
Protein SSXT SS18 1,92048 0,988246 
Histone H3 H3F3B 2,12753 -3,47977 
Lon protease homolog, mitochondrial LONP1 1,77697 -1,1821 
Transmembrane protein 205 TMEM205 1,7569 -1,23679 




Unconventional myosin-If MYO1F 2,44848 -0,495675 




Dynactin subunit 6 DCTN6 3,56454 1,02879 
High mobility group nucleosome-binding domain-
containing protein 4 
HMGN4 1,5482 
1,99868 
Lysosomal alpha-mannosidase MAN2B1 3,21644 -1,05135 
Fructose-1,6-bisphosphatase isozyme 2 FBP2 2,12745 -1,42789 
Apoptotic protease-activating factor 1 APAF1 3,31953 -1,94591 
Exportin-1 XPO1 1,95858 -1,28982 
FYN-binding protein FYB 1,93861 0,74564 
Actin-related protein 2/3 complex subunit 3 ARPC3 1,78974 -0,900927 
Serine palmitoyltransferase 1 SPTLC1 1,81264 -0,802845 
Syntaxin-7 STX7 2,52298 1,08607 
U4/U6 small nuclear ribonucleoprotein Prp3 PRPF3 2,22094 1,32621 
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A-kinase anchor protein 8 AKAP8 1,7539 1,7313 




Intron-binding protein aquarius AQR 1,87165 -2,78409 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 PLOD3 1,50536 -2,09434 
Toll-like receptor 2 TLR2 2,55182 -1,35848 
H/ACA ribonucleoprotein complex subunit 4 DKC1 2,01105 -1,06335 
WD repeat-containing protein 1 WDR1 1,97443 -0,770498 
Copine-3 CPNE3 1,55489 -1,74597 
DnaJ homolog subfamily C member 13 DNAJC13 2,36391 -1,6024 




Core histone macro-H2A.1 H2AFY 3,75721 -0,528851 




Interferon-inducible double-stranded RNA-dependent 
protein kinase activator A 
PRKRA 1,67361 
-1,5785 
Acyl-protein thioesterase 1 LYPLA1 2,42778 -1,43566 
U5 small nuclear ribonucleoprotein 200 kDa helicase SNRNP200 3,70966 -0,9646 
Eukaryotic translation initiation factor 3 subunit J EIF3J 3,2084 0,74896 
AP-1 complex subunit gamma-like 2 AP1G2 1,75285 -1,69973 
CAAX prenyl protease 1 homolog ZMPSTE24 1,85534 -1,77427 
Flotillin-1 FLOT1 2,09824 0,637147 
Glutaredoxin-3 GLRX3 1,75863 -1,28176 
TOX high mobility group box family member 4 TOX4 1,76785 1,06289 
Mitofusin-2 MFN2 2,60447 -1,35445 
Reticulon-3 RTN3 1,89289 1,07761 




NAD kinase NADK 1,51436 -1,90481 
AP-2 complex subunit alpha-1 AP2A1 1,86978 -0,968019 
Peroxisomal membrane protein 11B PEX11B 2,01916 -1,77389 
L-lactate dehydrogenase A chain LDHA 2,39312 -0,764338 
NADH-cytochrome b5 reductase 3 CYB5R3 2,49853 -1,81116 
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Coagulation factor XIII A chain F13A1 2,20862 -1,28347 
Aspartate aminotransferase, mitochondrial GOT2 3,79135 -1,20688 
Carbonic anhydrase 2 CA2 1,78639 -1,62715 
Alpha-1-antichymotrypsin SERPINA3 2,21278 -0,619604 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 
RPN2 2,10215 
-1,14633 




Aldehyde dehydrogenase, mitochondrial ALDH2 2,62104 -0,633041 
60S acidic ribosomal protein P0 RPLP0 2,41834 -1,03796 
Integrin beta-1 ITGB1 3,85059 -0,559403 
Glycogen phosphorylase, liver form PYGL 3,48884 -0,993727 
Nucleophosmin NPM1 2,82436 0,529038 
Cathepsin D CTSD 2,07031 -0,680798 
Calpain-1 catalytic subunit CAPN1 4,38378 -0,817368 
Tubulin beta chain TUBB 2,36384 -0,63584 
Beta-hexosaminidase subunit beta HEXB 2,28612 -1,46273 
Tyrosine-protein kinase Lyn LYN 1,78399 -1,02416 
Tropomyosin beta chain TPM2 1,64658 3,05169 
Fumarate hydratase, mitochondrial FH 2,46166 -0,662382 
Annexin A6 ANXA6 3,76216 -0,862628 
Beta-glucuronidase GUSB 1,79523 -0,847849 
Monocyte differentiation antigen CD14 CD14 4,40179 -0,876353 
Annexin A5 ANXA5 4,71894 -1,03138 
Glutathione S-transferase P GSTP1 3,9671 -1,00345 




Non-secretory ribonuclease RNASE2 3,36359 -2,21522 
Cytochrome c oxidase subunit 5B, mitochondrial COX5B 1,87498 0,748083 
60 kDa heat shock protein, mitochondrial HSPD1 2,59983 0,559345 
Histidine--tRNA ligase, cytoplasmic HARS 1,85024 -1,05112 
Inosine-5-monophosphate dehydrogenase 2 IMPDH2 2,17477 -0,604184 
Xaa-Pro dipeptidase PEPD 1,87983 -0,917921 
X-ray repair cross-complementing protein 5 XRCC5 2,34754 -0,580843 
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Hematopoietic lineage cell-specific protein HCLS1 2,11451 0,722314 
Alcohol dehydrogenase [NADP(+)] AKR1A1 2,12813 -0,77733 
Pyruvate kinase PKM PKM 2,99865 -0,588267 
Proto-oncogene vav VAV1 2,49495 -1,09344 
Carbonyl reductase [NADPH] 1 CBR1 2,88512 -0,574039 
Beta-galactosidase GLB1 2,20238 -0,907407 





Fumarylacetoacetase FAH 3,27055 -1,37436 
Calpain-2 catalytic subunit CAPN2 2,65472 -0,924127 
ATP-dependent 6-phosphofructokinase, liver type PFKL 2,37931 -0,72436 
T-complex protein 1 subunit alpha TCP1 3,04807 -0,777268 
Nucleolin NCL 3,95183 0,622529 
Hexokinase-1 HK1 2,94551 -1,09912 
Casein kinase II subunit alpha CSNK2A2 2,14554 -0,821901 
Nuclear factor NF-kappa-B p105 subunit NFKB1 1,90645 -1,10802 
Transcription factor BTF3 BTF3 2,318 0,827761 
Lamin-B1 LMNB1 2,43947 0,495247 
Integrin alpha-L ITGAL 2,48374 -0,843106 
Voltage-dependent anion-selective channel protein 1 VDAC1 2,86398 -1,27154 
Nucleoside diphosphate kinase B NME2 2,3839 -0,497314 
Cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 3,59401 -0,881662 
Splicing factor, proline- and glutamine-rich SFPQ 2,58002 0,475691 
NAD-dependent malic enzyme, mitochondrial ME2 2,23534 -0,596182 
Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 1,79399 -1,19811 
ATP synthase F(0) complex subunit B1, mitochondrial ATP5F1 2,16714 -1,39646 
ATP synthase subunit alpha, mitochondrial ATP5A1 2,64284 -0,513721 
Threonine--tRNA ligase, cytoplasmic TARS 1,75598 -1,26384 
Proteasome subunit beta type-4 PSMB4 3,1436 -0,890987 
Mitogen-activated protein kinase 1 MAPK1 2,61753 -0,784326 
Protein PML PML 1,8994 0,901271 
Elongation factor 1-delta EEF1D 2,36834 1,27918 
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HLA class I histocompatibility antigen, B-53 alpha chain HLA-B 2,7472 0,790903 
Leukocyte elastase inhibitor SERPINB1 3,1684 -0,859692 
Coronin-1A CORO1A 2,26719 0,63936 




Cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 3,39441 -0,660538 
3-hydroxyisobutyrate dehydrogenase, mitochondrial HIBADH 2,68811 -1,24953 
14-3-3 protein beta/alpha YWHAB 1,67599 1,40275 
Cleavage stimulation factor subunit 2 CSTF2 1,74765 0,979084 




DNA-directed RNA polymerase II subunit RPB9 POLR2I 2,39122 -0,987918 
V-type proton ATPase catalytic subunit A ATP6V1A 2,47061 -0,527253 
T-complex protein 1 subunit zeta CCT6A 2,77191 -0,578092 
Malate dehydrogenase, mitochondrial MDH2 3,06233 -0,384426 
Trifunctional enzyme subunit alpha, mitochondrial HADHA 3,86287 -0,949674 
Tyrosine-protein kinase CSK CSK 4,6583 -0,96348 
Isoleucine--tRNA ligase, cytoplasmic IARS 2,15091 -1,79023 
Enoyl-CoA delta isomerase 1, mitochondrial ECI1 2,26472 -1,16629 




3-ketoacyl-CoA thiolase, mitochondrial ACAA2 3,14964 -0,626313 
Glycerol-3-phosphate dehydrogenase, mitochondrial GPD2 2,4452 -1,19893 
Tyrosine-protein kinase SYK SYK 3,76973 -0,901762 
Chromobox protein homolog 5 CBX5 2,10899 1,08514 








Glucosamine-6-phosphate isomerase 1 GNPDA1 2,94327 -2,06763 
F-actin-capping protein subunit alpha-2 CAPZA2 2,63881 -0,444223 
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Glutamine--tRNA ligase QARS 2,08611 -0,715545 
Protein PRRC2A PRRC2A 2,70659 0,880562 
Signal recognition particle 9 kDa protein SRP9 1,84039 0,937887 
Alanine--tRNA ligase, cytoplasmic AARS 2,04659 -0,991529 
Serine--tRNA ligase, cytoplasmic SARS 3,79332 -0,612337 




Selenide, water dikinase 1 SEPHS1 2,74704 -0,910801 
Carnitine O-palmitoyltransferase 1, liver isoform CPT1A 2,06977 -0,688274 
Vasodilator-stimulated phosphoprotein VASP 3,56988 0,618461 
Dynamin-2 DNM2 2,5002 -0,707044 
T-complex protein 1 subunit delta CCT4 3,40388 -0,896176 




Host cell factor 1 HCFC1 2,33379 1,18256 
Fatty aldehyde dehydrogenase ALDH3A2 2,11063 -1,79095 
Peroxisomal multifunctional enzyme type 2 HSD17B4 3,64602 -0,989813 
Vesicle-associated membrane protein 7 VAMP7 1,57467 -1,24284 
Ribosomal protein S6 kinase alpha-3 RPS6KA3 3,99285 -1,39619 
Heterogeneous nuclear ribonucleoprotein M HNRNPM 3,1392 0,613544 
Heterogeneous nuclear ribonucleoprotein F HNRNPF 2,54012 -0,572794 
Hexokinase-3 HK3 2,82374 -0,598927 
Tricarboxylate transport protein, mitochondrial SLC25A1 2,76965 -1,40092 
ATP-citrate synthase ACLY 2,75442 -0,910218 
Coatomer subunit beta COPB1 1,98502 -0,845007 
Coatomer subunit alpha COPA 2,7146 -0,661044 
Methylosome subunit pICln CLNS1A 2,28733 1,07814 
Tyrosine--tRNA ligase, cytoplasmic YARS 2,22958 -0,564491 
Adenosine kinase ADK 2,61725 -2,0628 
Puromycin-sensitive aminopeptidase NPEPPS 2,30021 -0,695954 
IgG receptor FcRn large subunit p51 FCGRT 1,48641 -1,68566 
Methionine--tRNA ligase, cytoplasmic MARS 1,7956 -1,01287 
AP-1 complex subunit sigma-2 AP1S2 3,79375 -0,432019 
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Ribose-phosphate pyrophosphokinase 1 PRPS1 1,57901 -1,25981 
Ubiquitin-conjugating enzyme E2 K UBE2K 1,99856 -0,768679 
Actin-related protein 3 ACTR3 2,80776 -0,519711 
Alpha-centractin ACTR1A 2,68743 -0,886678 
COP9 signalosome complex subunit 2 COPS2 2,74075 -1,22798 
Ras-related protein Rap-2b RAP2B 1,65553 -1,45289 
Protein max MAX 3,66876 1,10512 
60S ribosomal protein L27 RPL27 2,11708 -1,35084 
40S ribosomal protein S7 RPS7 1,73713 -1,04498 




40S ribosomal protein S13 RPS13 1,94349 -1,10148 
Histone H4 HIST1H4A 2,47475 -0,484609 
60S ribosomal protein L23 RPL23 3,64318 -1,41488 




60S ribosomal protein L10a RPL10A 2,34054 -0,890566 
60S ribosomal protein L8 RPL8 2,59349 -0,765245 
Peptidyl-prolyl cis-trans isomerase A PPIA 2,46366 0,548413 




Serine/threonine-protein phosphatase 2A 55 kDa 
regulatory subunit B alpha isoform 
PPP2R2A 2,70699 
-0,640564 
40S ribosomal protein S21 RPS21 2,96434 0,700949 




SUMO-conjugating enzyme UBC9 Ube2i 1,81859 -1,01179 
Serine/threonine-protein phosphatase 2A catalytic 
subunit alpha isoform 
PPP2CA 2,60837 
-1,08207 
Nuclease-sensitive element-binding protein 1 YBX1 3,09281 0,670355 
Signal peptidase complex catalytic subunit SEC11A SEC11A 2,20306 -1,17365 
Tubulin beta-4B chain TUBB4B 4,74287 -0,732298 
Immunoglobulin-binding protein 1 IGBP1 1,80974 1,22574 
Glutathione S-transferase omega-1 GSTO1 1,97652 -0,715778 
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28S ribosomal protein S36, mitochondrial MRPS36 3,33779 0,712056 
Serine/arginine-rich splicing factor 3 SRSF3 1,921 0,936574 
Histone H3.2 HIST2H3A 1,77461 -4,14398 
Phosphate carrier protein, mitochondrial SLC25A3 3,70505 -1,12527 





DNA topoisomerase 2-beta TOP2B 2,03779 -1,06745 
Single-stranded DNA-binding protein, mitochondrial SSBP1 1,91343 -0,834792 
Tyrosine-protein phosphatase non-receptor type 11 PTPN11 2,18192 -0,681671 
Cytoskeleton-associated protein 4 CKAP4 2,28852 0,70689 
Mitochondrial-processing peptidase subunit alpha PMPCA 1,98611 -1,26331 
Vesicular integral-membrane protein VIP36 LMAN2 2,84059 -1,80768 
Heat shock protein 75 kDa, mitochondrial TRAP1 2,20098 -1,40645 
Protein flightless-1 homolog FLII 2,88011 -0,990279 
Lymphocyte cytosolic protein 2 LCP2 2,46652 0,61867 
Ubiquitin carboxyl-terminal hydrolase 4 USP4 2,06133 -1,2616 
Serine/arginine-rich splicing factor 9 SRSF9 2,43055 0,998055 
Serine/arginine-rich splicing factor 6 SRSF6 2,05764 0,961327 
Voltage-gated potassium channel subunit beta-2 KCNAB2 1,86417 -1,03915 
Cytoplasmic dynein 1 intermediate chain 2 DYNC1I2 2,2055 0,565186 
V-type proton ATPase 116 kDa subunit a isoform 3 TCIRG1 2,73568 -1,00609 
Diacylglycerol kinase zeta DGKZ 2,18066 -1,16102 
Stromal interaction molecule 1 STIM1 2,51708 0,529726 
Bleomycin hydrolase BLMH 2,4213 -2,6743 
Ubiquitin-associated protein 2-like UBAP2L 2,51005 0,794757 
Cytoplasmic dynein 1 heavy chain 1 DYNC1H1 2,08893 -0,718312 
Guanine nucleotide-binding protein subunit alpha-13 GNA13 3,499 -1,02924 
RNA-binding protein 39 RBM39 2,35072 -0,576593 
Protein disulfide-isomerase A5 PDIA5 2,29842 -1,65076 
Pre-mRNA-splicing regulator WTAP WTAP 3,47656 1,00766 
Septin-2 02-set 2,73964 -0,493138 
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Neutrophil cytosol factor 4 NCF4 2,8733 -0,884125 
Transcription elongation factor B polypeptide 2 TCEB2 2,40538 0,768398 
Ubiquitin-protein ligase E3C UBE3C 1,86271 -0,88677 
Scaffold attachment factor B1 SAFB 2,39901 0,49421 
Splicing factor 1 SF1 2,1738 0,615689 
ELAV-like protein 1 ELAVL1 1,98018 -0,963947 
NEDD8 NEDD8 2,17462 0,993753 
39S ribosomal protein L23, mitochondrial MRPL23 2,08323 -1,19942 
Hsp90 co-chaperone Cdc37 CDC37 2,66815 0,4987 
Kynureninase KYNU 2,52648 -1,09881 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial 
NDUFA9 3,07419 
-1,64304 
UTP--glucose-1-phosphate uridylyltransferase UGP2 3,22477 -1,51934 
Macrophage-expressed gene 1 protein MPEG1 1,79612 -0,976171 
Protein LSM12 homolog LSM12 1,8273 2,12645 
Putative oxidoreductase GLYR1 GLYR1 2,53032 -0,515744 
Presequence protease, mitochondrial PITRM1 2,03165 -1,9872 
RRP12-like protein RRP12 1,46907 -1,74184 
Engulfment and cell motility protein 2 ELMO2 2,17375 -0,731397 
FAD synthase FLAD1 1,5441 -1,37372 
Microtubule-associated protein 1S MAP1S 1,50047 -2,20191 
Atlastin-3 ATL3 2,73621 -1,72114 
Twinfilin-2 TWF2 3,72044 -0,856113 
Pre-mRNA-processing-splicing factor 8 PRPF8 2,36247 -0,940774 
La-related protein 1 LARP1 2,51979 1,01923 




Nesprin-3 SYNE3 2,01681 -0,676152 
Neurobeachin-like protein 2 NBEAL2 1,9098 -1,54626 
Vacuolar protein sorting-associated protein 13C VPS13C 2,82177 -1,00394 
Protein unc-13 homolog D UNC13D 2,62309 -0,666353 
Staphylococcal nuclease domain-containing protein 1 SND1 3,56017 -0,578772 
Eukaryotic translation initiation factor 3 subunit M EIF3M 1,65273 1,27447 
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Myosin-14 MYH14 1,99775 -1,29583 
KDEL motif-containing protein 2 KDELC2 1,85801 -0,96589 
Protein LYRIC MTDH 2,63261 0,528735 
Cullin-associated NEDD8-dissociated protein 1 CAND1 1,98656 -1,02126 
Ankyrin repeat and KH domain-containing protein 1 ANKHD1 3,26598 1,26275 
Chromatin complexes subunit BAP18 BAP18 3,35271 0,550715 
EH domain-binding protein 1-like protein 1 EHBP1L1 3,50919 0,47355 
Cohesin subunit SA-2 STAG2 2,061 -1,67936 
ADP-ribosylation factor GTPase-activating protein 1 ARFGAP1 2,31082 0,69476 
Serine/threonine-protein phosphatase 6 regulatory 
ankyrin repeat subunit B 
ANKRD44 1,72405 
-1,3506 
Parkinson disease 7 domain-containing protein 1 PDDC1 1,74804 -1,05617 
NHL repeat-containing protein 2 NHLRC2 1,87036 -0,990679 
Saccharopine dehydrogenase-like oxidoreductase SCCPDH 3,26675 -1,76188 
Dedicator of cytokinesis protein 8 DOCK8 2,96461 -0,979904 
Nucleoporin NUP53 NUP35 2,30424 0,672071 
E3 ubiquitin-protein ligase ZNRF2 ZNRF2 2,23478 1,35541 
Splicing factor U2AF 26 kDa subunit U2AF1L4 1,9353 1,16037 
Nuclear pore complex protein Nup133 NUP133 1,67874 -1,50911 
Sec1 family domain-containing protein 1 SCFD1 2,1278 -1,41071 
PEST proteolytic signal-containing nuclear protein PCNP 2,10385 0,909601 
GTPase IMAP family member 1 GIMAP1 1,6353 -1,29585 
UBX domain-containing protein 4 UBXN4 2,28551 0,822291 
Dedicator of cytokinesis protein 2 DOCK2 2,89095 -0,907926 
Translational activator GCN1 GCN1L1 5,08812 -0,941544 




Ubiquitin carboxyl-terminal hydrolase 7 USP7 2,19789 -2,06639 
Transcription elongation factor A protein-like 3 TCEAL3 1,95649 1,21938 
Synapse-associated protein 1 SYAP1 1,93329 0,731824 
Vacuolar protein sorting-associated protein 33A VPS33A 2,24503 -2,17975 
U8 snoRNA-decapping enzyme NUDT16 3,72204 -2,43102 
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RNA-binding protein 14 RBM14 2,82584 0,479664 
Vacuolar protein sorting-associated protein 35 VPS35 1,98205 -0,870391 
GPI transamidase component PIG-S PIGS 2,46451 -1,59008 
Chloride channel CLIC-like protein 1 CLCC1 1,8732 0,925029 
3-hydroxyacyl-CoA dehydrogenase type-2 HSD17B10 3,18232 -1,11657 
Histone H2B type 1-M HIST1H2BM 1,6272 3,96336 
Tyrosine-protein phosphatase non-receptor type 18 PTPN18 2,54493 1,35423 
Protein NipSnap homolog 1 NIPSNAP1 2,32923 -1,65041 
Serine/threonine-protein phosphatase CPPED1 CPPED1 2,09883 -0,678389 
Partner of Y14 and mago WIBG 2,88337 0,534585 
ADP-dependent glucokinase ADPGK 3,18701 -1,66906 
COP9 signalosome complex subunit 4 COPS4 2,42094 -0,875684 




Transmembrane protein 43 TMEM43 1,66103 -1,50206 
Charged multivesicular body protein 4a CHMP4A 2,67597 0,6476 




E3 ubiquitin-protein ligase TRIM4 TRIM4 1,64549 -1,45091 




Thioredoxin-related transmembrane protein 4 TMX4 2,10657 -1,46578 




Tubulin beta-1 chain TUBB1 1,84806 -2,94456 
39S ribosomal protein L44, mitochondrial MRPL44 2,38241 -0,816819 




Calcyclin-binding protein CACYBP 1,84313 1,10445 
Manganese-transporting ATPase 13A1 ATP13A1 2,7988 -0,725937 
Charged multivesicular body protein 1a CHMP1A 2,1657 3,30591 
Toll-like receptor 8 TLR8 1,93982 -1,10091 
F-box only protein 6 FBXO6 1,68245 2,35402 
Epimerase family protein SDR39U1 SDR39U1 1,86874 -1,4544 
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Phenylalanine--tRNA ligase beta subunit FARSB 2,17824 -0,909596 
Ethylmalonyl-CoA decarboxylase ECHDC1 5,48376 -1,26085 




ADP-ribosylation factor-like protein 8B ARL8B 1,74521 -0,919146 
ATP-dependent RNA helicase DDX18 DDX18 1,75179 -1,34623 
THUMP domain-containing protein 1 THUMPD1 2,116 0,930059 
Nuclear distribution protein nudE homolog 1 NDE1 2,31384 -0,925975 
UDP-glucose:glycoprotein glucosyltransferase 1 UGGT1 2,71331 -0,868593 
Adenosine deaminase CECR1 CECR1 2,8293 -1,63256 
E3 ubiquitin-protein ligase RNF181 RNF181 2,96526 1,61198 




Leucine--tRNA ligase, cytoplasmic LARS 3,54143 -2,0452 
Vacuolar protein sorting-associated protein 29 VPS29 1,98758 -1,37989 
Cathepsin Z CTSZ 1,90528 0,921716 
Protein NipSnap homolog 3A NIPSNAP3A 2,33258 -2,12625 
Signal recognition particle subunit SRP68 SRP68 1,75838 -0,944346 




Tyrosine-protein kinase BAZ1B BAZ1B 1,60595 -1,14092 
Hematological and neurological expressed 1 protein HN1 3,45913 0,744209 




26S proteasome non-ATPase regulatory subunit 13 PSMD13 2,83225 -1,62535 
Zinc finger CCCH domain-containing protein 4 ZC3H4 3,04223 0,711782 
Translation machinery-associated protein 7 TMA7 2,82494 1,09774 
AP-3 complex subunit mu-1 AP3M1 2,04928 -0,973914 
Thyroid hormone receptor-associated protein 3 THRAP3 2,15996 0,623545 
Acyl-coenzyme A thioesterase 9, mitochondrial ACOT9 2,79518 -0,808127 
Deoxyribose-phosphate aldolase DERA 1,83758 -1,00717 
Mitochondrial fission 1 protein FIS1 2,46892 -1,03182 
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Leucine-rich repeat flightless-interacting protein 2 LRRFIP2 2,55254 1,61824 
Mitochondrial carrier homolog 2 MTCH2 2,68093 -1,74277 
Sulfide:quinone oxidoreductase, mitochondrial SQRDL 5,68902 -0,769156 





Supplementary Table 7 
Urine Plasma 
102 - D-Tartaric acid 107 - L-Leucine 
106 - Theophylline 110 - D-Tryptophan 
107 - L-Leucine 12 - Uric acid 
11 - D-Aspartic acid 126 - Pyrrolidonecarboxylic acid 
110 - D-Tryptophan 130 - Caffeine 
113 - Allantoin 137 - L-Kynurenine 
119 - Asymmetric dimethylarginine 138 - Pyroglutamic acid 
12 - Uric acid 14 - L-Serine 
120 - Glucosamine 143 - Putrescine 
124 - 1-Methylhistidine 144 - L-Lysine 
127 - 4-Pyridoxic acid 151 - Norvaline 
128 - Quinolinic acid 156 - L-Arginine 
129 - Methylguanidine 16 - Citrulline 
130 - Caffeine 161 - D-Ornithine 
136 - Urocanic acid 168 - L-Histidine 
137 - L-Kynurenine 171 - L-Pipecolic acid 
139 - 4-Acetamidobutanoic acid 193 - Putrescine 
14 - L-Serine 20 - Inosine 
144 - L-Lysine 208 - N6,N6,N6-Trimethyl-L-lysine 
149 - Glutarylcarnitine 217 - L-Carnitine 
150 - L-Cystathionine 23 - L-Isoleucine 
158 - L-Fucose 25 - L-Glutamic acid 
160 - N-Methyl-L-glutamic acid 252 - Ornithine 
162 - Xanthosine 277 - L-Acetylcarnitine 
167 - Galactaric acid 298 - 2-Aminoisobutyric acid 
168 - L-Histidine 306 - 5-Aminopentanoic acid 
17 - Taurine 307 - L-Norleucine 
171 - L-Pipecolic acid 315 - 3-Methoxytyrosine 
192 - Gluconic acid 338 - L-Histidine 
194 - 4-Trimethylammoniobutanoic acid 339 - L-Allothreonine 
2 - L-Glutamine 35 - Pipecolic acid 
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217 - L-Carnitine 382 - Cortisol 
221 - Cyclic AMP 393 - Bilirubin 
227 - N-Alpha-acetyllysine 406 - Indoleacetic acid 
23 - L-Isoleucine 420 - Glycocholic acid 
240 - 1-Methylnicotinamide 424 - Chenodeoxycholic acid glycine conjugate 
259 - Asymmetric dimethylarginine 46 - Xanthine 
26 - Ascorbic acid 470 - Indoleacetic acid 
263 - Indoxyl sulfate 494 - Adipic acid 
267 - Thiamine monophosphate 499 - mono-Methyl glutarate 
27 - p-Hydroxyphenylacetic acid 50 - L-Tryptophan 
272 - N-Acetyl-L-alanine 513 - Indoleacetaldehyde 
274 - Hydroxypyruvic acid 52 - L-Proline 
275 - D-Mannopyranose, 2-amino-2-deoxy- 561 - 4-Hydroxycinnamic acid 
277 - L-Acetylcarnitine 59 - Niacinamide 
278 - Riboflavin 6 - L-Threonine 
290 - N-Acetylputrescine 62 - L-Phenylalanine 
291 - N-Acetylgalactosamine 67 - Hypoxanthine 
292 - N-Acetylglutamic acid 68 - Creatine 
295 - Acetylcysteine 73 - L-Lysine 
297 - Pantothenic acid 74 - L-Tyrosine 
298 - 2-Aminoisobutyric acid 77 - L-Valine 
305 - Ureidopropionic acid 79 - L-Homoserine 
306 - 5-Aminopentanoic acid 9 - L-Kynurenine 
309 - Adenosine 125 - Galactitol 
316 - Alpha-Lactose 132 - D-Glucuronic acid 
317 - 3-Hydroxybutyric acid 18 - Gluconolactone 
318 - Imidazoleacetic acid 192 - Gluconic acid 
337 - Guanidinosuccinic acid 2 - L-Glutamine 
338 - L-Histidine 206 - Glyceric acid 
34 - Malonic acid 26 - Ascorbic acid 
344 - Citramalic acid 274 - Hydroxypyruvic acid 
345 - Anserine 31 - Gluconic acid 
347 - 5-Hydroxylysine 317 - 3-Hydroxybutyric acid 
35 - Pipecolic acid 319 - beta-D-Galactopyranuronic acid 
361 - Stachyose 333 - Oxalic acid 
373 - Beta-Glycerophosphoric acid 34 - Malonic acid 
379 - Gluconolactone 344 - Citramalic acid 
38 - L-Methionine 379 - Gluconolactone 
380 - 4-Hydroxybenzoic acid 390 - Maleic acid 
381 - Tyramine 43 - Glyceric acid 
385 - Xanthurenic acid 444 - Methylmalonic acid 







Chiara Lavarello, Ph.D. Thesis in Chemical Sciences and Technologies. 
 
 
396 - Kynurenic acid 479 - Allyl isothiocyanate 
40 - Adenine 480 - Itaconic acid 
403 - Tryptamine 481 - Azelaic acid 
406 - Indoleacetic acid 487 - Diacetyl 
41 - 5'-Methylthioadenosine 5 - Citric acid 
416 - 2-Pyrocatechuic acid 504 - Citraconic acid 
420 - Glycocholic acid 519 - Sebacic acid 
444 - Methylmalonic acid 538 - myo-Inositol 
447 - 1H-Indole-3-acetamide 550 - D-Tagatose 
448 - Hippuric acid 72 - D-Malic acid 
454 - 3-(2-Hydroxyphenyl)propanoic acid 94 - trans-Aconitic acid 
46 - Xanthine 109 - Betaine 
468 - Dihydrobiopterin 11 - D-Aspartic acid 
470 - Indoleacetic acid 119 - Asymmetric dimethylarginine 
474 - Hydroquinone 120 - Glucosamine 
484 - Phenylacetaldehyde 124 - 1-Methylhistidine 
493 - Suberic acid 136 - Urocanic acid 
496 - N-Acetylleucine 150 - L-Cystathionine 
498 - Benzyl alcohol 166 - N-Methyl-D-aspartic acid 
5 - Citric acid 17 - Taurine 
50 - L-Tryptophan 184 - Palmitoyl-DL-carnitine 
500 - Indole-3-methyl acetate 194 - 4-Trimethylammoniobutanoic acid 
501 - Mevalonic acid 200 - Phosphorylcholine 
502 - Vanillylmandelic acid 21 - Gamma-Aminobutyric acid 
515 - 3-Hydroxyphenylacetic acid 22 - Cytosine 
518 - Salicylic acid 227 - N-Alpha-acetyllysine 
52 - L-Proline 240 - 1-Methylnicotinamide 
527 - 5-Hydroxyindoleacetic acid 259 - Asymmetric dimethylarginine 
555 - L-Arabitol 272 - N-Acetyl-L-alanine 
58 - Carnosine 275 - D-Mannopyranose, 2-amino-2-deoxy- 
6 - L-Threonine 297 - Pantothenic acid 
607 - Indole 351 - Trigonelline 
608 - Cholic acid 366 - D-Galactosamine 
62 - L-Phenylalanine 386 - 2-Methylpropanal 
632 - Cortisone 471 - δ-Valerolactone 
65 - L-Aspartic acid 48 - L-Cystine 
67 - Hypoxanthine 58 - Carnosine 
68 - Creatine 601 - 12-Hydroxydodecanoic acid 
70 - Guanosine 607 - Indole 
72 - D-Malic acid 65 - L-Aspartic acid 
74 - L-Tyrosine 70 - Guanosine 
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78 - Guanine 8 - N-Acetylneuraminic acid 
8 - N-Acetylneuraminic acid 87 - Diethanolamine 
80 - Pyridoxine 88 - 3-Aminoisobutanoic acid 
87 - Diethanolamine 92 - Creatinine 
88 - 3-Aminoisobutanoic acid 127 - 4-Pyridoxic acid 
91 - Guanidoacetic acid 160 - N-Methyl-L-glutamic acid 
92 - Creatinine 167 - Galactaric acid 
94 - trans-Aconitic acid 216 - 3-Phosphoglyceric acid 
  238 - Orotic acid 
 
263 - Indoxyl sulfate 
 
395 - Pregnenolone sulfate 
 
44 - Orotic acid 
 
515 - 3-Hydroxyphenylacetic acid 
 
555 - L-Arabitol 
 
557 - D-Ribose 
 
71 - Dihydrouracil 
 
